f10q0413_healthadvance.htm

0001213900-13-003203.txt : 20130619 0001213900-13-003203.hdr.sgml : 20130619 20130619154600 ACCESSION NUMBER: 0001213900-13-003203 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 9 CONFORMED PERIOD OF REPORT: 20130430 FILED AS OF DATE: 20130619 DATE AS OF CHANGE: 20130619 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Health Advance, Inc. CENTRAL INDEX KEY: 0001531477 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-RETAIL STORES, NEC [5990] IRS NUMBER: 460525223 STATE OF INCORPORATION: WY FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-177122 FILM NUMBER: 13921922 BUSINESS ADDRESS: STREET 1: 3651 LINDELL ROAD, SUITE #D155 CITY: LAS VEGAS STATE: NV ZIP: 89103 BUSINESS PHONE: 702-943-0309 MAIL ADDRESS: STREET 1: 3651 LINDELL ROAD, SUITE #D155 CITY: LAS VEGAS STATE: NV ZIP: 89103 10-Q 1 f10q0413_healthadvance.htm QUARTERLY REPORT f10q0413_healthadvance.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_______________

FORM 10-Q

_______________

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended April 30, 2013

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______to______.

Commission File Number: 333-177122

HEALTH ADVANCE INC.

(Exact name of registrant as specified in its Charter)

WYOMING		46-0525223
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

3651 Lindell Rd. Suite D155

Las Vegas, NV, 89103

(Address of Principal Executive Offices)(Zip Code)

_______________

702-943-0309

(Registrants telephone number, including area code)

_______________

N/A

(Former name, or former address and former fiscal year if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes o No x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company filer. See the definitions of “large accelerated filer,” “accelerated filer” and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer	o			Accelerated Filer	o
Non-Accelerated Filer	o	(Do not check if a smaller reporting company)		Smaller Reporting Company	x

Indicate by check mark whether the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. Yes o No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock. As of June 18, 2013, there were 24,520,000 shares of the issuer’s common stock issued and outstanding.

HEALTH ADVANCE INC.

FORM 10-Q

April 30, 2013

INDEX

PART I-- FINANCIAL INFORMATION

Item 1.	Consolidated Financial Statements	1

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	5

Item 4.	Control and Procedures	6

PART II-- OTHER INFORMATION

Item 1.	Legal Proceedings	6

Item 1A.	Risk Factors	6

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	6

Item 3.	Defaults Upon Senior Securities	7

Item 4.	Mine Safety Disclosures	7

Item 5.	Other Information	7

Item 6.	Exhibits	7

SIGNATURE		8

PART I – FINANCIAL INFORMATION

Item 1.

Financial Statements

HEALTH ADVANCE INC.

(A Development Stage Company)

FINANCIAL STATEMENTS

April 30, 2013

CONTENTS

PAGE	F-2	CONSOLIDATED BALANCE SHEET AS OF APRIL 30, 2013 (UNAUDITED) AND AS OF JULY 31, 2012 (AUDITED).

PAGE	F-3	CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE MONTHS ENDED APRIL 30, 2013 AND 2012 (UNAUDITED)

PAGE	F-4	CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE NINE MONTHS ENDED APRIL 30, 2013 AND 2012 AND FOR THE PERIOD APRIL 14, 2010 (INCEPTION) TO APRIL 30, 2013 (UNAUDITED).

PAGE	F-5	CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE MONTHS ENDED APRIL 30, 2013 AND 2012 AND FOR THE PERIOD APRIL 14, 2010 (INCEPTION) TO APRIL 30, 2013 (UNAUDITED).

PAGE	F-6	NOTES TO FINANCIAL STATEMENTS. (UNAUDITED)

HEALTH ADVANCE INC.

(A Development Stage Company)

FINANCIAL STATEMENTS

APRIL 30, 2013

F-1

HEALTH ADVANCE INC.

(A Development Stage Company)

BALANCE SHEETS

AS AT

(Expressed in United States Dollars)

	April 30, 2013 (Unaudited)			July 31, 2012 (Audited)

ASSETS
Current Assets
Cash	$	226		$	1,202
Prepaid expenses		-			1,164
Total Assets	$	226		$	2,366

LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities
Accounts payable and accrued liabilities	$	14,453		$	9,633
Advances from shareholder		29,848			25,466
Total Liabilities		44,301			35,099

Stockholders' Deficit
Capital stock, $0.001 par value; Authorized 100,000,000; Issued and outstanding 24,520,000 (July 31, 2012 - 24,520,000)		24,520			24,520
Additional paid in capital		138,080			120,080
Common stock issuable		33,000			-
Deficit accumulated during the development stage		(239,675	)		(177,333	)
Total Stockholders' Deficit		(44,075	)		(32,733	)
Total Liabilities and Stockholders' Deficit	$	226		$	2,366

The accompanying notes are an integral part of these financial statements.

F-2

HEALTH ADVANCE INC.

(A Development Stage Company)

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Expressed in United States Dollars)

	For the nine Months Ended April 30, 2013			For the nine Months Ended April 30, 2012			For the Period from Inception (April 14, 2010) to April 30, 2013

SALES		-			100			100
COST OF GOODS SOLD		-			69			69
GROSS PROFIT		-			31			31

EXPENSES
Professional fees		6,599			25,275			55,461
Office and general		11,814			6,442			19,298
Rent and occupancy costs		10,800			10,800			33,600
Consulting and management fees		33,000			38,000			131,000
TOTAL OPERATING EXPENSES		62,213			80,517			239,359
LOSS FROM OPERATIONS		(62,213	)		(80,486	)		(239,328	)
Foreign exchange gain (loss)		(129	)		55			(347	)
NET LOSS AND COMPREHENSIVE LOSS	$	(62,342	)	$	(80,431	)	$	(239,675	)
LOSS PER WEIGHTED NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED	$	0.00		$	0.00
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED		24,520,000			22,920,000

The accompanying notes are an integral part of these financial statements.

F-3

HEALTH ADVANCE INC.

(A Development Stage Company)

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Expressed in United States Dollars)

	For the Three Months Ended April 30, 2013			For the Three Months Ended April 30, 2012

SALES		-			-
COST OF GOODS SOLD		-			-
GROSS PROFIT		-			-

EXPENSES
Professional fees		5,000			2,200
Office and general		5,873			2,998
Rent and occupancy costs		3,600			3,600
Consulting and management fees		21,000			11,000
TOTAL OPERATING EXPENSES		35,473			19,798
LOSS FROM OPERATIONS		(35,473	)		(19,798	)
Foreign exchange gain (loss)		(129	)		(116	)
NET LOSS AND COMPREHENSIVE LOSS	$	(35,602	)	$	(19,914	)
LOSS PER WEIGHTED NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED	$	0.00		$	0.00
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED		24,520,000			22,920,000

The accompanying notes are an integral part of these financial statements.

F-4

HEALTH ADVANCE INC.

(A Development Stage Company)

STATEMENTS OF CASH FLOWS

(Expressed in United States Dollars)

	For the Nine Months Ended April 30, 2013			For the Nine Months Ended April 30, 2012			For the Period from Inception (April 14, 2010) to April 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(62,342	)	$	(80,431	)	$	(239,675	)
Adjustments to reconcile net loss to net cash used in operating activities:
Common stock issued for services		-			15,000			80,000
In-kind contribution of services		18,000			18,000			56,000
Issuance of common stock for services		15,000			-			15,000
Changes in operating assets and liabilities:
Prepaid expenses		1,164			25,000			-
Accounts payable and accrued liabilities		4,820			1,041			14,453
Net cash used in by operating activities		(23,358	)		(21,390	)		(74,222	)
Net cash provided by investing activities		-			-			-
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock		18,000			-			44,600
Advances from stockholder		4,382			12,846			29,848
Net cash provided by financing activities		22,382			12,846			74,448
NET INCREASE (DECREASE) IN CASH		(976	)		(8,544	)		226
CASH, BEGINNING OF PERIOD		1,202			8,843			-
CASH, END OF PERIOD	$	226		$	299		$	226

The accompanying notes are an integral part of these financial statements.

F-5

HEALTH ADVANCE INC.

(A Development Stage Company)

NOTES TO THE FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED APRIL 30, 2013

(Expressed in United States Dollars)

1.	NATURE OF OPERATIONS AND ORGANIZATION

Health Advance Inc. (the "Company" or "Health Advance") was incorporated in the State of Wyoming on April 14, 2010. The Company is a development stage company and is an online retailer of home medical products with operations in Canada and the US. On February 14, 2013, the Company effected a 10-for-1 forward split of the Company’s issued and outstanding common shares. The Company’s issued and outstanding common shares were therefore increased from 2,452,000 to 24,520,000. All per share amounts have been restated to reflect this stock split.

2.	BASIS OF PRESENTATION

The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the SEC instructions to Form 10Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. For further information, refer to the financial statements and footnotes thereto included in the Company’s annual report on Form 10K for the year ended July 31, 2012.

The Company is considered to be in the development stage as defined in Accounting Standards Codification (“ASC”) 915, Development Stage Entities. The Company has devoted substantially all of its efforts to business planning and development by means of raising capital for operations. The Company has also not realized any significant revenues. Among the disclosures required by ASC 915 are that the Company's financial statements be identified as those of a development stage company, and that the statements of operations and comprehensive loss, stockholders' equity (deficit) and cash flows disclose activity since the date of the Company's inception.

3.	GOING CONCERN

These financial statements have been prepared assuming the Company will continue on a going concern basis. The Company has incurred losses since inception and the ability of the Company to continue as a going concern depends upon its ability to develop profitable operations and to continue to raise adequate financing. Management is actively targeting sources of additional financing to provide continuation of the Company’s operations. In order for the Company to meet its liabilities as they come due and to continue its operations, the Company is solely dependent upon its ability to generate such financing.

There can be no assurance that the Company will be able to continue to raise funds, in which case the Company may be unable to meet its obligations. Should the Company be unable to realize its assets and discharge its liabilities in the normal course of business, the net realizable value of its assets may be materially less than the amounts recorded in these financial statements.

F-6

HEALTH ADVANCE INC.

(A Development Stage Company)

NOTES TO THE FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED APRIL 30, 2013

(Expressed in United States Dollars)

The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

4.	RELATED PARTY TRANSACTIONS

The transactions with related parties were in the normal course of operations and were measured at the exchange value which represented the amount of consideration established and agreed to by the parties. Related party transactions not disclosed elsewhere in these consolidated financial statements are as follows:

The Company paid rent and other overhead costs to a shareholder and director of the Company in the amount of $1,400 per month, totaling $12,600 for the nine months ended April 30, 2013 (nine months ended April 30, 2012 - $12,600). This monthly charge includes the head office rent, phone, internet and other administrative services.

Advances from a shareholder of the Company as at April 30, 2013 were $29,848 (July 31, 2012 - $25,466). These advances are non-interest bearing, unsecured and with no specific terms of repayment.

5.	SUPPLEMENTAL CASH FLOW INFORMATION

During the periods ended April 30, 2013, and 2012, and for the period from inception to April 30, 2013, there were no interest or taxes paid by the Company.

The significant non cash transactions for the nine months ended April 30, 2013 consisted of the following:

a) For the nine months ended April 30, 2013, the controlling shareholder contributed management services of $2,000 per month totaling $18,000 (nine months ended April 30, 2012 - $18,000);

b) On November 14, 2012, the Company received $10,000 in exchange for 2,000,000 shares of common stock at $0.005 per share. These shares will be issued in the next quarter;

c) In December 2012, the Company agreed to issue 1,000,000 shares of common stock valued at $0.01 per share for a total of $10,000 for web design services and repairs. These shares will be issued in the next quarter; and

d) In January 2013, the Company agreed to issue 500,000 shares of common stock valued at $0.01 per share for a total of $5,000 for consulting services. These shares will be issued in the next quarter.

F-7

HEALTH ADVANCE INC.

(A Development Stage Company)

NOTES TO THE FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED APRIL 30, 2013

(Expressed in United States Dollars)

6.	CAPITAL STOCK

On November 14, 2012, the Company received $10,000 in exchange for 2,000,000 shares of common stock at $0.005 per share. These shares will be issued in the next quarter.

In December 2012, the Company agreed to issue 1,000,000 shares of common stock valued at $0.01 per share for a total of $10,000 for web design services and repairs. These shares will be issued in the next quarter.

In January 2013, the Company agreed to issue 500,000 shares of common stock valued at $0.01 per share for a total of $5,000 for consulting services. These shares will be issued in the next quarter.

In March 2013, the Company agreed to issue 800,000 shares at a issue price of $0.01 per share. These shares will be issued in the next quarter.

F-8

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following plan of operation provides information which management believes is relevant to an assessment and understanding of our results of operations and financial condition. The discussion should be read along with our financial statements and notes thereto. This section includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our predictions.

Overview

The Company has incurred losses since inception and the ability of the Company to continue as a going-concern depends upon its ability to raise adequate financing and develop profitable operations. Management is actively targeting sources of additional financing to provide continuation of the Company’s operations. In order for the Company to meet its liabilities as they come due and to continue its operations, the Company is solely dependent upon its ability to generate such financing.

On February 14, 2013, the Company effected a 10-for-1 forward split of the Company’s issued and outstanding common shares. The Company’s issued and outstanding common shares were therefore increased from 2,452,000 to 24,520,000. All per share amounts have been restated to reflect this stock split.

Plan of Operation

We were incorporated on April 14, 2010 in Wyoming. Our business office is located at 3651 Lindell Road, Suite D#155, Las Vegas, NV, 89103. Our telephone number is 702-943-0309. We were founded by Jordan Starkman, who serves as our President and Director. In addition, Domenico Pascazi was appointed as a director in March 2011. On February 12, 2013, Mr. Pascazi resigned from his position as a member of the board of directors. Mr. Pascazi’s resignation was not a result of any disagreement with the Company or its executive officers, or any matter relating to the Company’s operations, policies or practices.

We are an on-line retailer of home medical products with operations in Canada and the United States, and with administration and infrastructure supported globally. Our strategy is to attract opportunities in the health care industry through the development and growth of our existing web site www.healthadvancemd.com. We believe we can operate more cost efficiently and compete as a discounter that delivers value and low cost branded lines of home medical care products together with valuable customer care that is currently missing in the marketplace. Our goal is to become our customers’ single source for low cost health care supplies, by meeting all of our customer’s needs.

We strive to offer health care professionals, medical distributors and consumers the highest quality brands and products at the most affordable prices. We expect to achieve this by forming relationships with suppliers that will be able to provide us with preferred prices once we are able to make bulk purchases.

In the fiscal year of 2013 and 2014, we plan to build our business across four key product categories including: (1) respiratory, (2) diabetes, (3) ostomy, and (4) mastectomy supplies. Our growth plan is to achieve net revenues within the first 12 months following our July 31, 2012 year–end.

We plan to complete a financing through a private offering for a minimum of $200,000 in the fiscal year of 2013. We have not yet entered into any agreements with any parties with respect to obtaining financing for the Company.

If we are unable to obtain financing on reasonable terms, we could be forced to delay or scale back our plans for expansion. In addition, such inability to obtain financing on reasonable terms could have a material adverse effect on our business, operating results, or financial condition.

If we are able to obtain financing, we plan to implement both online and offline marketing and customer engagement campaigns for both our traditional durable medical products and our four key product areas mentioned above. We intend to target consumers with on-line marketing, and businesses, including various senior care facilities, with direct mail, telemarketing and flyer campaigns. Initially, we will target small to medium size facilities. We also intend to launch our direct mail onsite flyer campaigns and outbound calling campaigns in unison to increase the frequency and awareness of HealthAdvanceMD. We expect to replace and expand any existing major wholesaler relationships we currently work with by the beginning of year two following our July 31, 2012 year-end. Further, during this expected time frame, we plan to establish direct-from-manufacturer programs for our four key growth markets. We intend to continue to run our durable medical products business through the existing wholesaler relationships given the large range of product SKUs in the durable medical product category where we carry no less than a selection of nearly 2,000 products. No steps have been taken thus far to secure customers for our products.

The Company has recently started the process of preparing for an online marketing campaign. The Company has a relationship with AGS Cybertech located in India who will manage and coordinate all of our online marketing efforts. The campaign will include internet banner ads, search engine optimization, and social media optimization. All banner advertising will be strategically placed with various click per view programs as part of our overall sales and marketing plan.

In our key growth areas we plan to focus on reducing and concentrating the number of product SKUs in each growth category in order to create leverage with our supply chain across selected relationships with respiratory, diabetes, ostomy and mastectomy suppliers. These new direct-from-manufacturer programs will primarily be drop ship programs and will essentially result in no new product inventory risks. They will be predominantly product substitution strategies where direct manufacturers carry the inventory risk in order to get shelf space within our business to consumer ecommerce property www.healthadvancemd.com and other sales channels. These programs will be based on committed but non-binding contracted volume from us with each manufacturer, but where the manufacturer still carries the inventory, marketing investment, and the majority of the time continues to handle drop shipments direct to our customers and sales channels.

The first tranche of these direct from manufacturer programs is expected to be with North America based manufacturers given a tendency for higher quality product, margins and their ability to handle inventory and direct shipments to our customers. We also plan to evaluate a select number of overseas supplier relationships if we identify that a select overseas direct supplier can and will meet our delivery, financing and quality and return warranty terms. As a result of these supply chain improvements we expect to increase our net revenues based on margin improvements of an average of 20-25% and this does not include factoring in even higher margins if we choose to source from overseas markets.

We expect that these new product launches will be outlined and planned within the 2013 fiscal year and the beginning of fiscal year 2014, once our financing is completed. During the next 24 months following our 2012 year-end, we plan to work with our manufacturing partners to develop and finalize no less than two new product lines within each core product group for respiratory, diabetes, ostomy and mastectomy supplies and launch them by the second half of year 2. Together with our manufacturer partners we intend to develop and test market and then finalize our packaging and product features and licensing requirements by the end of July 2014.

In addition to attempting to achieve supply chain optimization by the beginning of January 2014, which we intend to result in reduced overall cost of goods, we also plan to drive top line growth with a major marketing initiative for new products. No formal products have been discussed as of yet. By the end of July 2014, we intend to achieve the 3 key milestones outlined above including: (1) entering into new growth markets, (2) optimizing our supply chain, and (3) launching new product lines in our new growth. from existing product line sales in growth markets for respiratory, diabetes, ostomy and mastectomy supplies through a margin optimized supply chain; a contribution from our traditional durable medical products businesses through existing wholesaler channels and from new products launched.

We have estimated that we will incur minimum expenses equal to $15,000 in the year following our July 31, 2012 year-end in order to maintain our business operations. However, if we conduct a financing, we will devote the capital raised to operational expenses as indicated below. The Company will attempt to complete a financing for a minimum of $200,000 within the 12-month period following the Company’s 2012 year-end. Any capital raised will be through either a private placement or a convertible debenture and will result in the issuance of common shares from the Company’s authorized capital.

The Company is currently negotiating financing in the amount of $200,000 to further the Company’s business operations. Any capital raised will likely be through either a private placement or a convertible debenture and will likely result in the issuance of common shares from the Company’s authorized capital.

Results of Operations

For the Three and Nine Months ended April 30, 2013

For the three months ended April 30, 2013 and 2012 we had sales of $0 and $0 respectively. Operating expenses for the three months ended April 30, 2013 and April 30, 2012 were $35,473 and $19,798, respectively, and for the nine months ended April 30, 2013 and April 30, 2013 operating expenses were $62,213 and $80,517 respectively. The Company’s on-line web site www.healthadvancemd.com encountered a virus/worm and subsequently underwent extensive repairs that accounted for the Company’s lack of revenue.

Net loss for the three months ended April 30, 2013 and 2012 were $35,602 and $19,914 and for the nine months ended April 30, 2013 and April 30, 2012 the net loss was $62,342 and $80,431 respectively. The operating expenses were primarily attributed to professional fees, consulting fees, web design fees, rent and other general overhead. The decreased loss for the nine months ended April 30, 2013 compared to April 30, 2012 is attributed to the decrease in professional fees. Professional fees for the nine months ended April 30, 2013 was $6,599 compared to $25,275 for the nine months ended April 30, 2012. Professional fees for the three months ended April 30, 2013 and 2012 were $5,000 and $2,200, respectively.

During the period from inception (April 14, 2010) to April 30, 2013 the total operating expenses were $239,359 and the net loss was $239,675.

During the nine months ended April 30, 2013 the director’s contributed services totaled $18,000. These services were included in the calculation of additional paid in capital.

During the nine months ended April 30, 2013 we operated from a premises leased by a director. The costs of this premises and other general and administrative expenses paid on our behalf during the nine months ended April 30, 2013 totaled $12,600. These expenses are payable to the shareholder and included in current liabilities.

During the period from inception (April 14, 2010) to April 30, 2013, we had no provision for income taxes due to the net operating losses incurred.

Any sales generated consist of the sale of medical supplies from our wholesalers and any profit generated is derived from the margins on the products sold. We expect to generate increased sales once our advertising campaign begins.

Liquidity and Capital Resources

As of April 30, 2013, we had a cash balance of $226 and a working capital deficit of $44,075.

The initial use of the consideration received from the Company’s unregistered common share sales that occurred in the amount of $89,200 was allocated to offering expenses, professional fees, advertising/marketing, website and ecommerce platform development and working capital. The breakdown of the $89,200 received by the Company consists of $9,200 in cash received from sales of unregistered common stock and $80,000 of unregistered common stock issued in exchange for services. In July 2012, the Company raised $16,000 for professional and consulting fees. In November 2012, the Company raised $10,000 for professional fees related to the Company’s legal and accounting commitments. In December 2012, the Company agreed to issue 1,000,000 common shares valued at $0.01 per share for the upgrade and repair work of the healthadvancemd e-commerce platform, web design and consulting services. In January 2013, the Company agreed to issue an additional 500,000 common shares valued at $0.01 per share for consulting services. In March 2013, the Company raised an additional $8,000 for operating expenses.

The Company is currently seeking funding for our continued operations. The Company intends to raise a minimum of $200,000 and a maximum of $500,000 in order to continue the introduction of the www.healthadvancemd.com e-commerce site to the retail community and health care community. To achieve our goals the Company expects to commit the majority of its funding to the advertising of the Company’s web site. There is no assurance that the Company will be able to raise the capital required to complete its goal and objectives and the Company is currently seeking capital to further its business plan. We will likely to raise funds through either debt or issuing shares of our common stock in order to achieve our business goals. The issuance of additional shares or securities convertible into any such shares by us, any shares issued would dilute the percentage ownership of our current stockholders. There are no agreements with any parties at this point in time for additional funding; however, we are in discussions with various funders in the United States.

We believe we can satisfy our cash requirements for the next twelve months with our expected revenues and if needed an additional loan from our director, Jordan Starkman. We cannot assure investors that adequate revenues will be generated and there is no current loan commitment in place between the Company and Jordan Starkman. However, the success of our operations is dependent on attaining adequate revenue. In the absence of our projected revenues, we may be unable to proceed with our plan of operations or we may require financing to achieve our profit, revenue, and growth goals.

We anticipate that our fixed costs made up of legal & accounting and general & administrative expenses for the next 12 months will total approximately $25,000. Legal and accounting expenses of $15,000 represents the minimum funds needed to sustain operations. The $25,000 will be financed through the Company’s cash on hand, additional financing, net sales and if needed, an advance from our officer and director, Jordan Starkman. We do not anticipate the purchase or sale of any significant equipment. We also do not expect any significant additions to the number of employees, until financing is raised. The foregoing represents our best estimate of our cash needs based on our current business condition. The exact allocation, purposes and timing of any monies raised in subsequent private financings may vary significantly depending upon the exact amount of funds raised and our progress with the execution of our business plan. It is currently expected that the Company will spend an additional $175,000 in variable costs relating to marketing and business development that will be funded from future financings.

In the event we are not successful in reaching our initial revenue targets, we will need additional funds to proceed with our business plan for the development and marketing of our core services. Should this occur, we would likely seek additional financing to support the continued operation of our business. We anticipate that depending on market conditions and our plan of operations, we may incur operating losses in the foreseeable future. Therefore, our auditors have raised substantial doubt about our ability to continue as a going concern.

Recent Accounting Pronouncements

The management did not believe that recent accounting pronouncements issued by the FASB have a material impact on the Company’s present or future consolidated financial statements.

Off-Balance Sheet Arrangements

We do not have any outstanding derivative financial instruments, off-balance sheet guarantees, interest rate swap transactions or foreign currency contracts.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Not required for Smaller Reporting Companies.

Item 4.

Controls and Procedures

Disclosure of controls and procedures.

Pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), the Company carried out an evaluation, with the participation of the Company’s management, including the Company’s principal executive officer and principal financial officer of the effectiveness of the Company’s disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, the Company’s principal executive officer and principal financial officer concluded that the Company’s disclosure controls and procedures were not effective as of April 30, 2013 for the material weakness identified below:

●	Due to limited resources available, the Company currently does not have any employees except Jordan Starkman our Chief Executive Officer, Chief Financial Officer and director. As such, there is no segregation of duties within the Company.

It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events. Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Changes in internal control over financial reporting.

There have been no changes in our internal control over financial reporting that occurred during the quarter covered by this quarterly report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1.

Legal Proceedings.

We are currently not involved in any litigation that we believe could have a materially adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our company’s or our company’s subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

Item 1A.

Risk Factor

Not required for Smaller Reporting Companies.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

On November 14, 2012 the Company received $10,000 in exchange for 2,000,000 shares of common stock at $0.005 per share. These shares will be issued in the next quarter. These shares of our common stock qualified for exemption under Section 4(2) of the Securities Act since the issuance shares by us did not involve a public offering. The offering was not a “public offering” as defined in Section 4(2) due to the insubstantial number of persons involved in the deal, size of the offering, manner of the offering and number of shares offered. We did not undertake an offering in which we sold a high number of shares to a high number of investors.

In December 2012, the Company agreed to issue 1,000,000 common shares at $0.01 per share in exchange for the upgrade and repair work of the healthadvancemd e-commerce platform, web design and consulting services. These shares will be issued in the next quarter. These shares of our common stock qualified for exemption under Section 4(2) of the Securities Act since the issuance shares by us did not involve a public offering. The offering was not a “public offering” as defined in Section 4(2) due to the insubstantial number of persons involved in the deal, size of the offering, manner of the offering and number of shares offered. We did not undertake an offering in which we sold a high number of shares to a high number of investors.

In January 2013, the Company agreed to issue 500,000 common shares at $0.01 per share in exchange for consulting services. These shares will be issued in the next quarter. These shares of our common stock qualified for exemption under Section 4(2) of the Securities Act since the issuance shares by us did not involve a public offering. The offering was not a “public offering” as defined in Section 4(2) due to the insubstantial number of persons involved in the deal, size of the offering, manner of the offering and number of shares offered. We did not undertake an offering in which we sold a high number of shares to a high number of investors.

In March 2013, the Company received $8,000 in exchange for 800,000 shares of common stock at $0.01 per share. These shares will be issued in the next quarter. These shares of our common stock qualified for exemption under Section 4(2) of the Securities Act since the issuance shares by us did not involve a public offering. The offering was not a “public offering” as defined in Section 4(2) due to the insubstantial number of persons involved in the deal, size of the offering, manner of the offering and number of shares offered. We did not undertake an offering in which we sold a high number of shares to a high number of investors.

The above proceeds will be used to fund operations as discussed in our Plan of Operations.

Item 3.

Defaults Upon Senior Securities.

None

Item 4.

Mine Safety Disclosures.

Not Applicable

Item 5.

Other Information.

None

Item 6.

Exhibits

31.1		Certification of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1+		Certification of Principal Executive Officer and Principal Financial Officer of the Registrant pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS *		XBRL Instance Document

101.SCH *		XBRL Taxonomy Schema

101.CAL *		XBRL Taxonomy Calculation Linkbase

101.DEF *		XBRL Taxonomy Definition Linkbase

101.LAB *		XBRL Taxonomy Label Linkbase

101.PRE *		XBRL Taxonomy Presentation Linkbase

+In accordance with SEC Release 33-8238, Exhibit 32.1 is being furnished and not filed.

*Furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise not subject to liability under these sections.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Health Advance, Inc.

	By:	/s/ Jordan Starkman
		Jordan Starkman
		President, Chief Executive Officer, Chief Financial Officer (Duly Authorized Officer, Principal Executive Officer and Principal Financial Officer)

	Dated: June 19, 2013

EX-31.1 2 f10q0413ex31i_health.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER, PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002. f10q0413ex31i_health.htm

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, Jordan Starkman, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Health Advance, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an quarterly report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Dated: June 19, 2013	By:	/s/ Jordan Starkman
		Jordan Starkman President, Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial Officer)

EX-32.2 3 f10q0413ex32i_health.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER OF THE REGISTRANT PURSUANT TO 18 U.S.C. 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002. Unassociated Document

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Health Advance, Inc., (the “Company”) on Form 10-Q for the period ended April 30, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Jordan Starkman, Chief Executive Officer and Chief Financial Officer of the Company, certifies, pursuant to 18 U.S.C. section 1350 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: June 19, 2013	By:	/s/ Jordan Starkman
		Jordan Starkman President, Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial Officer)

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.INS 4 hlthadv-20130430.xml 0001531477 2012-02-01 2012-04-30 0001531477 2011-08-01 2012-04-30 0001531477 hlthadv:ShareholderAndDirectorMember 2011-08-01 2012-04-30 0001531477 2012-07-31 0001531477 us-gaap:BeneficialOwnerMember 2012-07-31 0001531477 2012-11-14 0001531477 2012-11-13 2012-11-14 0001531477 2012-12-31 0001531477 2012-12-01 2012-12-31 0001531477 2013-01-31 0001531477 2013-01-01 2013-01-31 0001531477 2013-02-14 0001531477 2013-03-31 0001531477 2013-03-01 2013-03-31 0001531477 2013-02-01 2013-04-30 0001531477 2012-08-01 2013-04-30 0001531477 hlthadv:ShareholderAndDirectorMember 2012-08-01 2013-04-30 0001531477 2013-04-30 0001531477 us-gaap:BeneficialOwnerMember 2013-04-30 0001531477 2010-04-14 2013-04-30 0001531477 2013-06-18 0001531477 2011-07-31 0001531477 2012-04-30 0001531477 2010-04-13 xbrli:shares iso4217:USD iso4217:USDxbrli:shares Health Advance, Inc. 0001531477 10-Q false 2013-04-30 Q3 2013 --07-31 Smaller Reporting Company 24520000

1202

226

8843

299

1164

2366

226

9633

14453

25466

29848

35099

44301

24520

120080

138080

177333

239675

2366

226

0.001

100000000

24520000

100

2200

25275

5000

6599

55461

2998

6442

5873

11814

19298

3600

10800

3600

10800

33600

19798

80517

35473

62213

239359

-19798

-80486

-35473

-62213

-239328

-116

-129

-347

0.00

22920000

24520000

15000

80000

18000 18000 56000

-25000

-1164

1041

4820

14453

-21390

-23358

-74222

18000

44600

12846

4382

29848

12846

22382

74448

-8544

-976

226

<div> <table align="center" style="width: 100%; font-family: times new roman; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0"> <tr valign="top"> <td style="width: 18pt;"> <div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">3.</font></div> </td> <td> <div align="justify"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">GOING CONCERN</font></div> </td> </tr> </table> </div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">These financial statements have been prepared assuming the Company will continue on a going concern basis. The Company has incurred losses since inception and the ability of the Company to continue as a going concern depends upon its ability to develop profitable operations and to continue to raise adequate financing. Management is actively targeting sources of additional financing to provide continuation of the Company’s operations. In order for the Company to meet its liabilities as they come due and to continue its operations, the Company is solely dependent upon its ability to generate such financing.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">There can be no assurance that the Company will be able to continue to raise funds, in which case the Company may be unable to meet its obligations. Should the Company be unable to realize its assets and discharge its liabilities in the normal course of business, the net realizable value of its assets may be materially less than the amounts recorded in these financial statements.</font></div> <div style="text-indent: 0pt; display: block;">  </div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.</font></div>

<div> <table align="center" style="width: 100%; font-family: times new roman; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0"> <tr valign="top"> <td style="width: 18pt;"> <div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">4.</font></div> </td> <td> <div align="justify"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">RELATED PARTY TRANSACTIONS</font></div> </td> </tr> </table> </div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The transactions with related parties were in the normal course of operations and were measured at the exchange value which represented the amount of consideration established and agreed to by the parties. Related party transactions not disclosed elsewhere in these consolidated financial statements are as follows:</font></div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 18pt; margin-right: 0pt;"> </div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The Company paid rent and other overhead costs to a shareholder and director of the Company in the amount of $1,400 per month, totaling $12,600 for the nine months ended April 30, 2013 (nine months ended April 30, 2012 - $12,600). This monthly charge includes the head office rent, phone, internet and other administrative services.</font></font></div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"> </font></div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Advances from a shareholder of the Company as at April 30, 2013 were $29,848 (July 31, 2012 - $25,466). These advances are non-interest bearing, unsecured and with no specific terms of repayment.</font></font></div>

<div align="center"> <table style="width: 100%; font-family: times new roman; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0"> <tr valign="top"> <td style="width: 18pt;"> <div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">6.</font></div> </td> <td> <div align="justify"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">CAPITAL STOCK</font></div> </td> </tr> </table> </div> <div style="text-indent: 0pt; display: block;"> </div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On November 14, 2012, the Company received $10,000 in exchange for 2,000,000 shares of common stock at $0.005 per share. These shares will be issued in the next quarter.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In December 2012, the Company agreed to issue 1,000,000 shares of common stock valued at $0.01 per share for a total of $10,000 for web design services and repairs.  These shares will be issued in the next quarter.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In January 2013, the Company agreed to issue 500,000 shares of common stock valued at $0.01 per share for a total of $5,000 for consulting services. These shares will be issued in the next quarter.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In March 2013, the Company agreed to issue 800,000 shares at a issue price of $0.01 per share.  These shares will be issued in the next quarter.</font></div>

<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <table align="center" style="width: 100%; font-family: times new roman; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0"> <tr valign="top"> <td style="width: 18pt;"> <div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">5.</font></div> </td> <td> <div align="justify"> <div align="justify"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">SUPPLEMENTAL CASH FLOW INFORMATION</font></font></div> </div> </td> </tr> </table> </div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"> </font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">During the periods ended April 30, 2013, and 2012, and for the period from inception to April 30, 2013, there were no interest or taxes paid by the Company.</font></font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"> </font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The significant non cash transactions for the nine months ended April 30, 2013 consisted of the following:</font></font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 18pt; margin-right: 0pt;"> </div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">a)       For the nine months ended April 30, 2013, the controlling shareholder contributed management services of $2,000 per month totaling $18,000 (nine months ended April 30, 2012 - $18,000);</font></div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">b)      On November 14, 2012, the Company received $10,000 in exchange for 2,000,000 shares of common stock at $0.005 per share.  These shares will be issued in the next quarter;</font></div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">c)       In December 2012, the Company agreed to issue 1,000,000 shares of common stock valued at $0.01 per share for a total of $10,000 for web design services and repairs.  These shares will be issued in the next quarter; and</font></div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">d)       In January 2013, the Company agreed to issue 500,000 shares of common stock valued at $0.01 per share for a total of $5,000 for consulting services. These shares will be issued in the next quarter.</font></div>

1400 12600 12600

500000

5000

2000

10-for-1

2452000 2452000 33000 0.005 1000000 0.01 10000 0.01 15000 15000

10000

2000000

-19914

-80431

-35602

-62342

-239675

<div> <table align="center" style="width: 100%; font-family: times new roman; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0"> <tr valign="top"> <td style="width: 18pt;"> <div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">2.</font></div> </td> <td> <div align="justify"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">BASIS OF PRESENTATION</font></div> </td> </tr> </table> </div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the SEC instructions to Form 10Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. For further information, refer to the financial statements and footnotes thereto included in the Company’s annual report on Form 10K for the year ended July 31, 2012.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The Company is considered to be in the development stage as defined in Accounting Standards Codification (“ASC”) 915, Development Stage Entities. The Company has devoted substantially all of its efforts to business planning and development by means of raising capital for operations. The Company has also not realized any significant revenues. Among the disclosures required by ASC 915 are that the Company's financial statements be identified as those of a development stage company, and that the statements of operations and comprehensive loss, stockholders' equity (deficit) and cash flows disclose activity since the date of the Company's inception.</font></div>

800000

0.01 11000 38000 21000 33000 131000

-32733

-44075

EX-101.SCH 5 hlthadv-20130430.xsd 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Balance Sheets link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Statements of Operations and Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - Nature of Operations and Organization link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Going Concern link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Supplemental Cash Flow Information link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Capital Stock link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Nature of Operations and Organization (Details) link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Supplemental Cash Flow Information (Details) link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Capital Stock (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 hlthadv-20130430_cal.xml EX-101.DEF 7 hlthadv-20130430_def.xml EX-101.LAB 8 hlthadv-20130430_lab.xml Document and Entity Information [Abstract] Document and Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag Current Fiscal Year End Date Current Fiscal Year End Date Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Balance Sheets [Abstract] Statement of Financial Position [Abstract] Assets [Abstract] ASSETS Assets, Current [Abstract] Current Assets Cash Cash CASH, BEGINNING OF PERIOD CASH, END OF PERIOD Prepaid Expenses Prepaid expenses Prepaid expenses Assets Total Assets Total Assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' DEFICIT Liabilities, Current [Abstract] Current Liabilities Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current, Total Due To Related Parties, Current Advances from shareholder Due to Related Parties, Current, Total Liabilities Total Liabilities Total Liabilities Stockholders Equity, Including Portion Attributable To Noncontrolling Interest [Abstract] Stockholders' Deficit Common Stock, Value, Issued Capital stock, $0.001 par value; Authorized 100,000,000; Issued and outstanding 24,520,000 (July 31, 2012 - 24,520,000) Common Stock, Value, Issued, Total Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Additional Paid In Capital Additional paid in capital Additional Paid in Capital, Total Additional Paid in Capital, Beginning Balance Additional Paid in Capital, Ending Balance Common Stock Issuable Common stock issuable Common stock issuable. Development Stage Enterprise, Deficit Accumulated During Development Stage Deficit accumulated during the development stage Deficit accumulated during the development stage Stockholders' Equity Attributable To Parent Total Stockholders' Deficit Total Stockholders' Deficit Liabilities and Equity Total Liabilities and Stockholders' Equity Total Liabilities and Stockholders' Deficit Capital Stock, Par Value Capital Stock, par value Capital stock, par value Common Stock, Shares Authorized Capital stock, shares Authorized Common Stock, Shares, Issued Common stock shares issued after stock split Capital stock, shares Issued Common Stock, Shares, Issued, Total Common Stock, Shares, Outstanding Common stock shares outstanding after stock split Capital stock, shares outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Statements Of Operations and Comprehensive Loss [Abstract] Income Statement [Abstract] Revenue, Net SALES SALES Cost Of Revenue COST OF GOODS SOLD COST OF GOODS SOLD COST OF GOODS SOLD Gross Profit GROSS PROFIT GROSS PROFIT Operating Expenses [Abstract] EXPENSES Professional Fees Professional fees General and Administrative Expense Office and general General and Administrative Expense, Total Occupancy, Net Rent and occupancy costs Consulting and Management Fees Consulting and management fees Consulting and management fees. Operating Expenses TOTAL OPERATING EXPENSES TOTAL OPERATING EXPENSES Operating Income (Loss) LOSS FROM OPERATIONS LOSS FROM OPERATIONS Foreign Currency Transaction Gain (Loss), Before Tax Foreign exchange gain (loss) Foreign Currency Transaction Gain (Loss), before Tax, Total Net Income (Loss) Attributable To Parent Net loss NET LOSS AND COMPREHENSIVE LOSS Earnings Per Share, Basic and Diluted LOSS PER WEIGHTED NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED LOSS PER WEIGHTED NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED Weighted Average Number Of Shares Outstanding, Basic and Diluted WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED Statement Of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Net Cash Provided By (Used In) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Issuance Of Stock and Warrants For Services Or Claims Common stock issued for services In Kind Contribution Of Services In-kind contribution of services by controlling shareholder In-kind contribution of services Value of services contributed to the company. Proceeds From Issuance Of Common Stock For Services Issuance of common stock for services The cash inflow from the issuance of common stock for services. Increase (Decrease) In Operating Liabilities [Abstract] Changes in operating assets and liabilities: Increase (Decrease) In Prepaid Expense Prepaid expenses Prepaid expenses Increase (Decrease) In Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total Net Cash Provided By (Used In) Operating Activities Net cash provided by operating activities Net cash used in by operating activities Net Cash Provided By (Used In) Investing Activities Net cash provided by investing activities Net Cash Provided By (Used In) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES Proceeds From Issuance Of Common Stock Proceeds from issuance of common stock Proceeds From Related Party Debt Advances from stockholder Net Cash Provided By (Used In) Financing Activities Net cash provided by financing activities Net cash provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease) NET INCREASE IN CASH NET INCREASE (DECREASE) IN CASH Nature Of Operations and Organization [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation Of Financial Statements Disclosure [Text Block] NATURE OF OPERATIONS AND ORGANIZATION Basis Of Presentation [Abstract] Basis Of Presentation [Abstract] Basis Of Accounting [Text Block] BASIS OF PRESENTATION Going Concern [Abstract] Going Concern [Abstract] Going Concern [Text Block] GOING CONCERN Discussion of company's ability to continue as a going concern. Related Party Transactions [Abstract] Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] RELATED PARTY TRANSACTIONS Supplemental Cash Flow Information [Abstract] Supplemental Cash Flow Elements [Abstract] Cash Flow, Supplemental Disclosures [Text Block] SUPPLEMENTAL CASH FLOW INFORMATION Capital Stock [Abstract] Equity [Abstract] Stockholders Equity Note Disclosure [Text Block] CAPITAL STOCK Nature Of Operations and Organization (Textual) [Abstract] Nature of Operations and Organization (Textual) Stockholders' Equity Note, Stock Split Forward split for issued and outstanding common shares Common Stock Shares Issued Before Stock Split Common stock shares issued before stock split Common stock shares issued before stock split. Common Stock Shares Outstanding Before Stock Split Common stock shares outstanding before stock split Common stock shares outstanding before stock split. Schedule Of Related Party Transactions, By Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Shareholder and Director [Member] Shareholder and Director [Member] Shareholder and director. Beneficial Owner [Member] Shareholder [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Related Party Transactions (Textual) [Abstract] Related Party Transactions (Textual) Related party transactions textual. Periodic Payment For Rent and Other Overhead Costs Monthly payment for rent and other overhead costs to a shareholder and director Periodic payment for rent and other overhead costs. Payment For Rent and Other Overhead Costs Total payment for rent and other overhead costs to a shareholder and director Payment for rent and other overhead costs. Supplemental Cash Flow Information (Textual) [Abstract] Supplemental Cash Flow Information (Textual) Supplemental cash flow information textual. Periodic In Kind Contribution Of Services Monthly in-kind contribution by controlling shareholder Periodic in-kind contribution of services. Stock Issued During Period, Value, Conversion Of Units Common stock shares received in exchange, value Stock Issued During Period, Shares, Conversion Of Units Common stock shares received in exchange, shares Common Stock Shares Received In Exchange Per Share Par value of common stock shares received in exchange Common stock shares received in exchange per share. Common Stock Shares Issued For Web Design Services and Repairs Common stock shares issued for web design services and repairs, shares Common stock shares issued for web design services and repairs. Common Stock Par Value For Web Design Services and Repairs Par value of common stock shares issued for web design services and repairs Common stock par value for web design services and repairs. Common Stock Value For Web Design Services and Repairs Common stock shares issued for web design services and repairs, value Common stock value for web design services and repairs. Stock Issued During Period, Shares, Issued For Services Common stock shares issued for consulting services, shares Issuance of common stock for services, shares Common Stock Par Value For Consulting Services Par value of common stock shares issued for consulting services Common stock par value for consulting services. Stock Issued During Period, Value, Issued For Services Common stock shares issued for consulting services, value Issuance of common stock for services Capital Stock (Textual) [Abstract] Capital Stock (Textual) Capital stock textual. Common Stock, Capital Shares Reserved For Future Issuance Shares to be issued in next quarter Common Stock Par Value For Future Issuance Par value of shares to be issued in next quarter Common Stock Par Value For future issuance. EX-101.PRE 9 hlthadv-20130430_pre.xml ZIP 10 0001213900-13-003203-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-13-003203-xbrl.zip M4$L#!!0````(`,E]TT*'L(B^8AD``,C,```4`!P`:&QT:&%D=BTR,#$S,#0S M,"YX;6Q55`D``XH*PE&*"L)1=7@+``$$)0X```0Y`0``[#UK<^,VDM]3E?^` M\V5W,U66)5(/2_;,;&G\BI,9V[$\F^0>-061D(4+12H$:5NYJOOMUPV0$DA3 M$BE1MCQQ/DPLDD`_T"\T@,;;?SZ,''+'?,$]]]V.L5?;(C[#C_`?PG@ MYHJ#H1,,J7WW;F<8!..#:O7^_GYOR*AZ2EV+[5G>2`*K->JUG6^_B=HYW/T] MT0C[W//\6_BV5J_BZSY@L4/(M`E^8?-I([U!JZI>)CY_!.*^+K\W.IU.5;Y- M?"YXUL?0N5']]=/'GC5D(UKAK@B0JITD6GP!*;,FLS9<>`W3V%_42GVA-[+9 MV&<6CO#<=ITJ]2W?V^CMG,8VX]GMX,6<)NS!&F:WP3=S&G'WCHD@ MNYEZ-Z>A2[DELMO)5]C,>-Q,<"N[$;R8UR08^W/:P)LYC4)1N:5T/&TWH*(O M1S]Z,8>J!V>!K/WZ,:4+8>`O$#%XB^*/Q@*5Z$!(U;AF`R*5ZB`2P<6J5QW[ MWICY`6="4W;503`90VO!1V-G^FSHLP'TJ.Q*);8G>P_"WB'5V&X=>6[`'@+2 M8U:`)B\R:+28:9V7PS10H/96,NW+-7/0DE\! M.I,;G[J"2I$5'R;ZF^X#%U]Z0^JSH>?8S.\"-AR<`%CT3VS49_[3,#_B';L= MP=/X@0T@P;]PBP<*%V)S>*]BE<@:'>0G<^=]I-P'B^A]6\T$K8V&AN5+EYFN M^'(Y^%(W*C^&SO:IFHIK@BD/]L'ES%K/WI;,@R*:\P%"X@%("74N[R$X_OI4 M)FZ32>@F=.4I!]UH5"Z\NZT7?#`81J-\'AR%(O!&6\N$1]$)LJ%>Q&BF^%:Z MT3QFUO:Q+2T[YD;T)Y*=;67"8]DI&MFF^%:^PZ6NG&-L%=L2LE-7<[Q-RLY6 M,B$E.Y(-163G$=_*E1TPUZ>LOWUL2\N.N1&?-=6?3]3??A[4-ZP_6\F$Q_I3 M+ZH_]8WH3S(5L^U,*^:PZD^35=AJIIE%I]5/Q;375,S6IF*V1V8BS[:EJI;V M;$D>E.S=5].3C@/D+.)!;7MYH`Q(?54>X"+T9Y<_ M6H'&Y]]^<_Y_QG^=_NOJ!_;`CINM_?9OU^P/_OY\^#N[._F=^P_WS7VKT6A8 MS6;3NOG?X?NSD\/6V[-WA\99J],PVOMOSXQW9X<-HWE^T#DX.?_AL+'?2BQQ MAP@:.2\P;@.G%#T?,2I"G[V/;*)\&6,?OXM_8Q\9/7[N'3_J+MJC<@#OBO?V M!?BHXNEIOS:_@Q%\KWU\$8YP3Y/GKPCZ47M\>,Q<;\3=K&[S,BC1136)?8IR M'/H3AZ%S3TC%6YOQ@Q,IF]?LEHL`XHO@@HX8B>3I&C<\S)WH_2#W6)&NVF2U M2\Y=:^]M=5Z?B,CLW1'@XE/GW+79PT]LD@^@KFUSNXKA''M6B!3?3,8YZ0'- M^UEUK+>-^^O"`QL?GCKT-E^'`^H(IGI,M$ZC>"75^42Y_7Q=S^*&),:)KM)P M3KFPJ*,^.85G(A^LG^M)&(^ZR8;S&Z-^`2CX;Q:<:35E M%:1Y725E]90[S#^"Q[>>GU-2>R/J0"-RS<:>'^!6R"-O-*;N1!?<1+\I]?!& M(\_M!9[UN[1/XC(,T`G@MLM,#!['>@2U7WX366)B,XL#7N+=#G@_L]$T09]J M"4U:`!7QB^<71U0,%V"A[Q:888'6.XF"8=;,MU6]TR)`-'8O`F*:K=5A:&'C M(ACM=J->`B&+N65V.BO#T..>%(P'P0]<[KS;"?R0[53U3J]\-J;<5X/S0N[;-47>NX>T3$/J%-.,%=K:UC,@;0F,GE->[U=%)EC=L<<;XSSCEY`;QE$Q,P? M^URP8ZE\`7B#J>UW]P4B9K* M@P.7.J"6#L7)'R',<$J/[Y8!+`NY56+"(KAI1@,\Q*4/G`6&2_L!$WTY&UR% M=UJ&34,44SE[-=U4YP!?(K;SF+EY;-6TNAL&0\_G?S*[,$\SY_)&+?HO$\4T MS!)0RV3@IE$[%R(LBV.S[,<2<&MBE)]1Y6"4+TU4+J/F)8E6Q*U4ELW!K4<= M)J[!C[@ANV#9(7OZ7%[^5$*>WM,'V!9&!3J)J<[7HZI(@J0X567WGK$/H`RV M'7DBN!Q$[TH6A>5]%Q&$EIX!U'M>AYPBHU24G'+[+CC^N;AUYGM"7/G>@)=M M!9;U7&3@ZUKPH?6[.B%%!J88(67V7'#`%01<1"K-IZA.IM6$OD9`$[&9M@V0O4>NFGE=:&W1!&6LV&RTC'WA5#,7! M1+(]XJY<"@_X'8L6,M87O4Y'R_$M@;8N8H7<5*-A/AEBA:2VO5]_)HXM"56, MMM%X,LR*QE$=/V*9C`10*VOL\V.ONZ0#\"4!QZ$:%JUYK&?JG0"XE7LZ'; MP-)I7^*[3=,H%WI!F3/KG7JS4Q2#<]?R1NPC1)1KRUYEGO#-8*R"0A$!K+1K MC7:K=!2*2&%EGAB6R84E*,R3Q?50*"B/%11(,[\\G'H^X[?N453@3%LX/J/< MQ:\_L`%\;SXYN(24PS,ZS(UQ(9;8!X:(*5F_L MKXWS"?5=4$D1+^Y\H();\C"B$P9S%@`6:EKV0I.I%IIFZ"Z!NRZ*"W5K.U!< MJ$_;@>)"#=H.%)?IC([E@G3=+Z`[0X#1O0,?=\^^XQ<2E?^10/EI_IF$DT\2%@&\2ZR)K%.O#+ABQM&OK M,2VNFW#N_L1=&Y'P>3_$&`>ZB+Y??V3;$LD\L$K$:4D:ZXEP*KIBT"J$UG3< M7A(PEF[;;YD(I?$8RBBZ4)`^4K$_*!0OP8->5[^&Q7OO#Y+-@ M]KD[S1%U8>IZ5XXP54RCWM'&(3_HC2&\-'-6;[:?&>&BR8C]AFF:&\+Y7-XH ML+94++!SI0(N8F#7!+R6<0>@%F.V./6]T2P6TS8:ELSD,N#EBI-R`UP?NX)J MTFBT2D%0/TAUS/HEK`>;[48K&[$TK!)Q6L*L>MM\`I2*KK,E#Z#E16N.HI]R M%P:]7(>7&LO\D#>&[[*3'8F!?A9\"PK!?J/16.ZAEZ",32!0PO_AJ94[ZC", MH&3QB72$5<+2:+.A33N*P-X@SDN"BLY^:PM0+FH@TF495D'ZTK^E+O^3XBP: M\!">PVWY`SJ#29^`7JB:84="1AUY5`>/CHEC+BS'P[(Z-X#_!R>O:WW_=RI&;P7_D^'GX^!PAY"^Y]O,1X81BSF.&%-+WKL6 M_1Y3VXY^:]CXY"[")?#&^@L[C50;HQEM4!063(B/JWW*TX M;)!ZXF-R4SV2?6%/2$KDLNKD^ONS?GE18]T+X[) MY?59]^+\/^23(J15`U__@;*H_4ZTRZ!\_H!/Z>^C:A01`#H:'_Z[T:IE8)X6 M,8G-`8FP.20%T9`2_$2"*/M,EKR2%:_(]\&0D9VHOL\.\7RRD_QLYPVYIP+` M6IX_]M3]B-PEV$R:(^(-R"\3+.9UBQ<>@J7A#C$:NP3KM>R1&_@NZIUP02@8 MTND!6*!-'(F#8QCV$[74D>!- MX=;DGOD,X?MRS1_'1WH8FPQ`!(BYVVB:NS!5(H%'S,9NTZSAKTQ>=!W@*)8+ ME"=/Z4AF>'H> M_,P##D&G%O/=5X_X`CUB_85ZQ+/+\XLSKYMM7S@:6%R'\0FQ4B MIG9%LW-C7&GQT?""_97^3/<']]Q1Q3TXGO`#.TS)K1>=!D:K0_I4\*11A[ZE MX\0-6S8!ZX7[@`5'WXO_C&4IR]A1J1SZ).55T.9.@5+Q"*C-QLRU!0G'T!4' M3LN5S'K`WL=JZAQ#E&@L\J$S7/<@5"'2=*(' M3K-GQ%@@27>T!1%@%7R&12D@;+"1=RERL<$,0M+UHVOS'"10L1?)SF+P;71A M-!&A-=38M<0,E*Q,?V&=QD(9$"[V&7$]J;6^#&PA)`@>ZVX?='Q@7"VIOZ(6.G6B9:`4QF@-T*$E2 MM?10,H$?UA"5Z9$@1Z&VZ_DC65PH](4,N?MX1SD3D>2Z@(OJ6@*ZD[69X"L- M3$3`".35!Q,(PNU`<^25@A#'?3ZS4-7B('^.V2PJXXOD*"VI2V2V'$_X'.*: M[8!L#T8W0(_@A#8:*I@)V4B=>NUCQCDRH3A..#ZX%2LR0R@]E@-CS`!/QS;[8UWG!R3J^[US6_DYKI[T>L>R3S85QW\OV"C M&VA&0R6,?&52R%A5DU2IE'F.-A4RRV^CBO9@7E6[NWL>-5(03,)E12 M@]F:@\4NP4P)B(15MP2S*Q!"B&&4\J&W/E/)EOY$-HS0W"/7&MZ3)%WH06QE M$>$#Y@AV/YQ1I58]HH0+IHBR_)!,_@C@H^-X]^(@AX-_"J'X.N5R4[(>^V;< M,4AD/5>91,0T(<&H8<@H;LT6,-P@7U2E_%19O2@.51>4I6>AW$V)\'?&;J-6 MDVG#$2`SA##4"V`P($[YSC!W6_`NGJJYF,J5'PF"DRD[RA'7:RKM2KY?\H4Y M$X+*[,\(S!N<<<.$33:'H#8.HU4T)6>!1%+M#2#F89(INV0\]%R&X3[X>HR= M9URBB;(`1$2;6S.\U?/KQB8$,ZEO7R>-&^@S6BP1*ON>5*R4+F$6)TCK@'0K MWYF=W7:C3;[_,01)KAN+I-]L[C9:+2G]3"9M(OAHQ5W/K4C1!M<"83K%NJ.[ M$*P+9BFOA7X,'2',FL6863@;@.F^/Q)J[C"F$W0).65^EN`O$*HGJJ<]JNUY MX05LW?@^%="GP_W7^'ZS<7+KA<;W1]VK\YON1]*[N3SZ:8,A_:K)D:\NC7?I MD@L(3>0-DM%*K)E,QT)(PL`7VQ!9R$5,E6.((FZ,,N1"IWP3K8W*&%LMELHE M2K"WW^&9U>9LG3,VG/%J:I0AC)9>X\D`\([\$8(]8_YK5O=)Q.'<)<3LCL6``,;9T;!8>JJ%4%M*H??'S/^@1B1V#<-/Z3/E.> MQ/%%YB+ZJS1MJ33]2%VYR^/Q#H^T,#7+$J7F5))PUATZ:H4LGDF\&IYM%95/ MU+>&.02EG104D`@:O8&@WI)9HY2(;-9D:(6"\X;2Z=VSIXYWWPO'8W7/(G5F M3<1ZX?<&KJX\GGTXN<)IQU.W]0$X_7OY" MSB].+Z\_S=E`NX#1+VF1X;D35B_9/VVB3W4EC5IDD.<5LC.TNS+Z5=$X_A5G M=E4;E?*:;6@"-YEN+K>IJAR7ZY%I:@J[H0^`ITQ71ZL=D=,MG'!]T6/[*L3K MK7O@7$WN:8"N79!!"V\432R0Y5Z-D(MS`E?)HKRM6A`#/R*G60*,_-6V^^G*F+XP MUI:OEJYWD4K\[9NG6X;Y"^X.Z*\E6\^5N"QA*ODJ51N4*JLDB_47R80>8H>O M\K@Y>;1SRR.9(X9?<0HU>8P[3Q9,/W6F#GESZTHMF$.,<0W_Z[KV)"L&%+NM>G6"SE:#X M.2A]HJ%=B=)$[EC=TJCR`DHV]-L;M:*-"\LH&!4P&;DJEC93UVL60R('^O)> MTQ*P7W:+5"'P639DH]4ES5J6TN>MYIB]JJ`NJI0GH7,M#,2GJ)>M5LSZU=DT MYSY15?%\"2KJ;DZC43EE_2)U=&<JB"+D9E##7A":397H&0JD1F$ M+"EH;V02DP^7.82L2L7"\\LB]&-BBUX;I-^RN M`;;@56&MFKD!:I=>#U9OE`-VA2O!6OK%OG-!XX41XG(0596.:EJ\GMY]&?M_ MS!>ZN_]#MW?>P_)U5][0,<(O69),IK:[ M(T#!HC)+_1@?[@[P*'&BQD_OY`B>"X@CHUT)@4<@W!D!S3_OD:Y$$/!Q)KNJ M>DVZ-(3CQ)L2TKT//"^`3QG6B_@CY$AR?Y)%3#;5*M$^@K^#.?4^L`0/`O;& MW(WJ1LP6P'6(XM4!X#3>3`]#`VZS0P:20>C+TYL:6W:Q5AT\BLIF9!]Y3G!.[E+"I8RH MZWC@LXH34=<-)4%CSP^P&E0TC#]--YI,&/6CU?W$<;[7[=Q/9CNT>DZ:E.'! M^NEQ_\?5**F`AR`M:ORU\*2'F3/JVP+ZM6<%5+Z/Y<*L'79[1]-?QN$;TC&: MN^18`]&3($Z@0W6B/UTL#-#Q4$M%V,=$7:`*]41ZC[,#-@#Y4J>WXPI`!'CE MNE*I\`2W!@TLP(A15YWJI%S(((N..2ZRH9CJ%;;2F(!N*N,352RR96$:?9^5 M#Y#<$*GHPM1-[2*T9PMF"4,$C$%FR-.IZ>I,_Q#9RHF#A.(%\&0A&VCCJ9(, M"XJ([D:V-@*A=?>XE`,V\=F0@62`5<'R;+MJG3)*2?^#,)F4)M^C0%@\>*.: MX=ZR`=9(F%9<4!71\%-5W4VR(JJ-FJ3T_P=?)DG,E"1&$QEEU3ZBQ^P,B5/8 MX"%HFA0\].966@*,"5@G&_^HC6\B<5?,6:#U*TEV!N$!)R*; M\+D7-@[EF)>".!//+94:][H;HHWBX;2*$A>1TF1.N)F3%(XX9Z.(V_6!VT$Q,C!4$E2T M*!_4BLDH*2FPTMN#%"J!C-;',!LL"M*2 M:04B@5P`4$L#!!0````(`,E]TT)&*EJ&PP4``/I&```8`!P`:&QT:&%D=BTR M,#$S,#0S,%]C86PN>&UL550)``.*"L)1B@K"475X"P`!!"4.```$.0$``.U< M;6_;-A#^/F#_P7`_.XJ3;EB"9H7KQ(6Q=`GRLNU;04MGFRA%:J3DV/]^1UEN MK1=34F)(=)9/2>3C\;E[CG?DBY"@EW?XS2:HK&]<_.SISX4Q15]%S% MXZ^%2\+8A%)1JRG'_7Z)[W3_M%2>5WM`RD8W,&T$T]_'JX"N.@J MZ@=,PXZ?S25,$0,+Y\1;H(K^Z?'[TV.MX-U]2$+P@8Y/%NG+)D#F2M4KOHR!6^HZ6]Q_CA\A)N:DFG"A,SX;3UCS,J4J$E,3:1Z,T("I*A_X@`+U>:) M=N])[[B?,/0N>?QUH!2$:J.9D0FP>+ZO60&G86!#HN8&6.N/LV0-9!H?D>Y& M!_Z:8RH=T8F$HR+?C[7U*!*V&3^5PB_V3#*A*`(HI`<24P5FBDCAY"+0B@GK M=IZ`SN8A?M1MVK.W$@)"O:ME`%S!,)(2@]+@ZAWR%OM^!^*$C)-2,IS,^O]_ MI81K2B:4(0@PY8645-,A/'!=$?%0W9(5F3`8<`^?R`B\+53E@5U+2ZOA7D!) M-N9K&6-C6KJ,X$'<`7H7O%LBJU%H&F0[8R;L;ZFJ4LS!Y=H[C%K<*8 M#TE`0PUI=[G8->)`>-F)OW*RJ49/T7DN>;@=&V.E(EVI"CQNE+;@W++ M"=^GJ4E\O-\='[VWNI_>7>%&M]8NH'QHTPOPN>3-S]IP.'^60JE;*:;4 M=().236^X@@#=8=ED$?P)YA@YB1;76L%KLTMJRQ@&S/>4"B,U`2E\2R:DK/= M]QFXY=FLQ5U5ZVGB)@")$_-9TBXW;4(*9)M_>R&FH%1,X`B,:/.BK0;N3D?G M7U]D<=N8.SX#1WN8;C1[/N54A3*.W\0Z4\DI&WD8-)6:L>>^RGY6.QY"`TQ& M*W.Y38L=!A]IS'MNM9B;6EQ%3$/$6/A".![E=6[?D9TJC;+;XY5,*.]EO!5= M/ELCN<8M396RNRW=>+Y_YG&B]2C.NSB7R;=!VUAK][%'.P`>"J"_[=U-<8&5 MKE("R8>E>"&SVV/YA4UT1[-S]I\[M08 ML.PO*)KR:?6HP!OS[\MX@.PORM[*U%'2]#I_27%H<:W6)"6[D#/6V)B`X_L` MN"YNIO&[%SP[_4TD)IQ081:Z![F@+J@;.62$^B;B:NHY<&)K6MO@I98Q_X-R M#P_#H:232$^#&!-`A@:`>=B!LE7-N`:;,VB#"^"I$1KY(X2V;N=L18^!K'IJ M#IR\>L96;O0TF6*Y*X'HJS?KGV.>_DZ`*:N6#CU0=JL;F##Z2_FANU5*JUQY MKT5T-86OCOYJ9B=!\:N-_5Q;#Q-CO@#UTL-$H9(W3Z>=E%Q.?)FG"Y6T$+; M7'S-;[S+QMJ8O0SD%;P;+[/0QB/?-NRMK_RL+F%B_NJE:=@KHC)OG,W?@&H] M"6H`6*;U#WUEH6,%QIKXW6D=G9SKY#Q0F,KM]F*:NCW_P&#?_P'4$L#!!0````(`,E] MTT)CZ@3`;0,``(T8```8`!P`:&QT:&%D=BTR,#$S,#0S,%]D968N>&UL550) M``.*"L)1B@K"475X"P`!!"4.```$.0$``-U876_:,!1]G[3_$*7/(03:K:"R MBI95FM2*BE)I;Y&37(@UQT:V4^B_GQT2:-8$`H1^[`EPKH_/NBY^TLUK%_W]T^^"%$R,)42$3]]2P- M4S3/Z70Z=O)4A0K<%,P`@F1OKU)\D<[B$,0T6&^[$'UDIXC3R+T`]A2YGLUUHR*6#"*2.T M%9S($`5/"L1I-T_;S01H!`1)".X1E\]CCJA`OCZAQ``DPD28QK\:-;<0T!)+ MGX4-GT5VHG(;5L)6E1&F6(_?*FHYTK"00`,(,MH:M(YUDXN!^;FUB#Z*&2], M?Y+Z"1)>DO]86%.$9LH'IV4#D2(;T8EL64TG/7M/TF&WA(Z2"[\D1");DR`/ M2,+$K3K551>?_<9R]-47Q`2&D[(\7SWGGB!OO?,*-.Z%YSJI\/7VZ?-\"E2M M9:NF9;?3/3;A+-K=C)0`JTDBXP'PGJF`8Z'HLYD.1HJCL3P`NCZC4I7)3P+J M6%(7O("I_F*NGA,F(.B9DL?P]ENEFMK^`N]1`P4@;NLHFV+#U?)ZD^QM=?'. MV4U\^79Y3^<'N=9FB\/+8+=]%"?+VJW*M5Z2]^W>K67]1QZY@ZR]/JY7^2;^ M[&<0KD_&^/=LX]NS%;ZJ2/.899L*HBRDAZK M9B=&I.$R=70AMJHB.!^^RAN5&LI]Y!W?+?N@6,68/\>/>ON\X;QD?I0Q3R4 M(?#A$W#UIA9<,R&+&KT]4-SO[^':'KDO-F]'I;4<@!O].\RW"BK./[=?U136 M4VBUW%2#&,;LA6X,XCKF?/EJ6'9=E4]R.Y_2OVK"4MM:9;;9^;^HDJ'L_W;U MXR]02P,$%`````@`R7W30A"9]&25&P``6(`!`!@`'`!H;'1H861V+3(P,3,P M-#,P7VQA8BYX;6Q55`D``XH*PE&*"L)1=7@+``$$)0X```0Y`0``U5UM<]LX MDOY^5?ZFJ(H2.8.36I(RK'W MUR]>2(DD2!`@00#^,#6.U-WJA^QN-!H-X*>_/3WXX!%&L1<&/Y]=O[XZ`S!P MPXT7['X^^[P:7_SE#/SME__\CY]\+_A][<00((8@_OGL/DGV[R\OOW___OII M'?FOPVAW^>;JZNUE1GA&*=\_Q5Z!^OO;C/;Z\N^?[I;N/7QP+KP@3IS`/7%A M,55\U^_>O;LDWR+2V'L?$_Z[T'42`J%1+U!+@?]UD9%=X(\NKM]P][':Y+/["&ZK=?"CZ!+S7P9PYR1P@^7_ MY0+]!)7_7^G'9P`3?5Y,CE*(A$-\>8@O=HZSIT)\9PW]3-39Y2^@!^W>8?37 M?\YK=X=_EE6Q_"C?%611)J2C#@WG,/+"S2AHIVJ)6ZO.R\2)D@Y:Y_@UZ;T* M$\=OI7&.4Y.N4]CNV1[Y=#U3%(IANV=ZXE2H:\+J*?T@3T\0CR/X[SOT^P7- MX%,"@PT.?_13S,F)Y30&XC&`#$VA6Q#FX\$@C$HX_>3>V3PB.-=OK_[T]HJ` M23_\[39T#P\P2`8!2X22:.`"`_\IL<^^4O&?R" MMA&,PT/D0BGH]`T4%7+6D@JAD18QXX$>!A>?EV>_9&S`"3:`,H(<)_B6\?[_ M3U0%=8A0"K(.CY9O#[!!5+0M)W(S]="?#MZG36:[`U5L%:;)FP7Y,=H-B^ MP?%][#N[&E,MT6@RT;)FY==\_!Y@`A,&V4U#7>97^8;S9EXK(8_1)W&"T#+5F MLV6UK36"_$A)B$V:KDJ]=9MOC854&7"95*<)4^<1-^("O1$S+FK<9!!I4+/$ ME-7I;L:<*ZREWJ#SQ#K*4V//A]$0C0&[,.(7ITJ46DM392UKBCR$#&1TYJI2 M2M356Y"JM`.V'%4DTU(_#1\>PF"9A.[ORWL'O;;9(<$]'+AUA%],Y3+JK:SR M,=25+`D7(&SG@#*"'*?!JJL6/)HKL@)V5E&>Y7&U1#81;<&0$&:?AU>0V1I?YCQ2O;B\:Q#$R&P%_*1-J]`Q&1V:Q M@1!88/O-FBZ7H]72I`57O_"RK9:HS%AE6MH6-DZ&7KN-LAI7F^HYR)8=;+'9 M9LTSC2F]>1.NL8YJ2RX3ZS;HH1/?<^R7?JW17%-]F'>,/C9EASI5VC/-P=)J M#98?S\'-Z,-D.IU,/X#9&,Q'B\GLMB==3\W7[30=36_K==3IO'E/*/LJ^4ZW M:\XCN'>\S>AI#X,8IH&"XZLU]!J=MT[C\IM/Z4!*J+VXV59?V)>^2:ZWOG=M M=3H5UX;+7E9-;";%:\SI#"1QM5F;V0RM0BVRXZ,F(=/C+*U4TY\K\I-#[;9_ MYSEKST<3?Q@/@@VII]V'_@9&\>B/@Y<\"\QXQ$5H]!\)7&5[R;'2_02$P8+I M41=,D\'-Y&ZRFHR68(#RK^5J-OSUX^SN=K18_@!N1^/)<+(RZ1RR=EAV'V%^ M@PXF7D3@,9EQHN9)>8[8IIJ"%(9,[1R3)4XA6&+@<&C/JEPW/`1)/'>>G;4/ MD5>B3Z(#W+`Z\E(O&2DZ\S,I=$P2EW*#E)V,,ZD`4.5(QO(]-3#W.9A."M.O M]S%-":/>5W@.2")J-`.5=TDF3940H3OBW![@*EQ`G^R9=R*Q`,-CTAA/N+HS MK5<'B(P)I.0@I3<>+*0P##:/>+$X!MA,08S7\&G"9B882#__I/[Y6^#IS:Y0 M=FP.A\&462Q'-I44\[-@"S+>VFI(GVH*^5M')0UEX0)IMX'FH_)<=Q*X_@$W M0LW#B'1T)$GDK0\)'K!7X12A#H,$/0&DRFX2)!"]9)%)J>H?TMK0I/@9L2U# MIQ]("T;GX/@;(/T1D/\5/((7?P=D/V3!M%GK$_L!W,*MYWI,YJ*WGZH//V([ MKY3^BO;F@5/;Y1?'/U3M?ZLGU=E4P.K)U'H*7;&$"KEL'*.YC+&^`P&MG;V' MQ\:8JOW?5Z^OKJ[1_#H"CYCCKV!P2.[#R/L7RDNOKZ[.K^A_?TV1D5EJ>&J5 M!6_^=/X_;P@)>/6_!_\9O+T^!_CE@XO<=S^:21*ZO<6:-+RSZC(=&QT!W,"= M%P3X/:6]M09;.CI"&5%[J\&AM>VC)H8Q+2!E.NT5U,V&=.0Z_MSQ-I,@]7U> MM;2.0V=EM%9KM@2040),BM(?D!(;*W>VT9VT7G@!<'O27:R8V?JI>\>G;D'` M5`/#HK"I!I`]P;,A)C'EXAIRB5#*.]&ICM;:\411D M=*;.8Y12F>2DP.M+Y4VZ7Y><>=B/SJ]-'@_),>;R:9!5I-I76^`C],,]?B,H MM._@",]-]Y$7PW0R/W#1^SJ0@O+M(4+QJ\S!6Y51(%SGZHV*9\&L,IQ(`*$! M)['G6<4$Y"0#*AHPC,86A/IY+!2XDP.^H<"3>P@V.?"Q6O!5QYZ_,/!:UZ"4 M!0AFK:J[9/-5>JE*N^%J>6/]-NV1+->WYX[)]6@A''2I2:@:K6V\R"%P=-W6I26K)'G+1LK]YI> M](OAN!1FP2)>"Q1Q`PI#"R5-'L)9.ZEE->CP],B@TU*IF*.S7&8N33B<,"WQ`!4?2)N`F%(=^H,R:.3S`LQGV!+M/*^$'&8=('CEJ+V']OW1VR M@YN8[K0RG1J]EW9O;-%O9=_L_1ZFJ&T=N1Y-I1/W]28DNTHZ6)$%3=X-3MP8 M?U)RX[&'?["D&)O)*,0_A+':B/H\3K)=/!)"40A*^3XR>R-3`Z[*\!3V^';: MM8\IL32K.B/4@[.G2T+F3%,A'MTQ>A*XX0,\'A,IL#N@ED-C9*[7NO:(SQC, MMF"&C)9T%=":&WH3^PC>PR#V'B&X"V,;SG,4QT8IP>D44SO.*VTPJ;([U)%K M7[AS?!@OX",,#G`*N?MCRI0ZE^P8+T%B@TNCG1>W*+YM\"^C7IER\0UV^NGTU$JK+#L M)GD2W4Z2SB^"77;\J-X4A[/.75@FF3#(#1W^>CZ=)LBM=H M*F6[KF?0?WIQN(5Q3'9[C"'W[`Z65.N9Q8R>[(&Z)Q*`:]X"`^0W/CZ_:O/@!1[VF<1[A*D7\7*9)DZ=^4TC"F;$IAST MM+("3Q:UC65"TEAFVZWGTH/7=I394([4PUNP8'E1T$681*N!37ORY;J'O1.X MS_SJ79%,9XI5U(\Q\NQKHY6[!B47N,Q,CI;(Z("+IJ5&AZ*J]\XD3WD:97M2 M@_C@XXP,N<`G)W!VI(!=DQ$)<6G=H\K3GJV39=3D[9_HC21-2C`\G#!4)5.= M,8CO8E4'PO"VUD9_8+>WUK,8G[O+S-G-SM6%YNC63,PKM%W-5H,[,)N/%H,5 MOMFH;H*N)\U3J;'1DH)P*<&6H3#E?0MM[ETH7Y5YA0_8E: MLG['5?H.UW7'B]FGS)9G4]->UUE?(S['&G*MU^5(=?O=.(R@MPOH@;_N\RIR M@MAQ<8;RP?$"K-(-W"*:E?/$\4?0[`CZ/Q>PI60\^MZ<^OCF[.@[M+"&E&[48K0(9S?$_5'6>[+&^8RY2#TGY3#FD/!SB`"B3!5]'DP\?5Z-;,/W\Z0;]>S8& MRX^#Q6@)9I]7RQ7R$3S-O``W@^5D2%SF=G+W&3&8<6X;D.J,"(+N5HX136RZ MH\97E"W((-V=G!Z>%C#:+8ENN6V(8@'D[8"-<:8UIC+%IP)`JDD0$7A M_M%TXW5Q"XXM44G=`\@\=_`%S;T_C%Y(K+(7O\X(ULWURX&MI33]I[&EVTIF M6WS1^]@/OXOTY/'9M)[0QM6_=K<3CDF8`1`."]KS6@,)!8'H/?VLV:K8<]`X M/`:FYEB)>10^>ANXN7G^',/-)#A6*`=NXCW2(YR:G:6-,+V3?'FL53-I8H:9 M&'#S#%YA26`2_`A.I?^3-`N<3@GTX6#Y$8SO9E^+=7Z7_\ M&7I?9_I#@*T@HJ]?7B`Q\!B3$$3'QQBDA4S\*?[;Q4_P@!^:%X#P^,R`V\E05*.S@,+)!$R6_U3?E)K(&>OX+I")@,@(2"3`F81H'*,G6#0$2QS M8P/R\RU"&*>L1@\W:&.JS)$'4D(4M:M.@E^]8#/$=PSB%2PO#-#/I[]5X5-B M;!H;5AOT9P_'`)@>Y!F(]]084?=2%.\PIM8@+G['(-P\"#0CSCP!K)]!_E[1 M/F_7%NS)58S06%NN)`YRXFGAU1P1H>B%TA9\:P,:D?=.\&RT2U)6)^!%?YWFJ M6^3O-3!?N.B,=T@:).-2G2&.84*/D/-/4HS6'-H9;\59;#)2S'OH/(+X5M;F MS=S-K$:]D,$AZ'8':GO" M1DO\1Z#['%`G!>KW"%2H_ZC7U^R)OV8+MCQT\_+F("8DS=YN"R5=%I9V5ZCI MJK"_E:(&)YGU[S.8=PUNE0* M,1]=JK%)1I>C$'NCBSA.)KIX1W16NR#'2@5=L$J")2XX]@(G#(=3(?6MU,*V+*@P_(D&3C)E+\>P?%3`5Z]9YTV M(FFWIFCP1-3VB,BZ6MV:FN%S4\4LKN(@U09&D\ZS@#XNMLZ=*'F^A6O>^,9G M,^0R%?KSO25E`(0#8!8;_$0`QF#SB$TG=9'X=#VW+5Y19TH\AV!X[,T`E61^ MEF9\:C(]^],[T4G8]HC.TA)/S]CLS%N[YZOZ+UI">@V"#?[?Z(^#]^CXN.%_ M3FY@+!?!.0%&3HS.:YKD\+%W>R+C)!?ZX3]R$LX!E0$J5DZ,W?74#2L^-6QOR#Z3Q'!E,U@@YVZ;1S_%/%VF*W&FC1K[.(SX5/1'&RIWD$,&* MNT?S/VA!;:LO_'FYYZ`@F3R&O&P\3S]*![F;6^W8]:_4:9C#094(?U%QY-:+ M73^,D7NLX%-RX_/+;>I_ZJ5$E^KGU,G19C6.=OHI\`W_&""_]C*#DMACFPY6 MGQ;?,J-D5!CYRPXJ[GD0`\*G9M8!*RIO&>%QZ)[O$UU2;O%6:UAK*BZ^HMCCA/9!K3=/F`KRO_X<8T";S M9[SA'^__]X(#!`[Z&.S(BW&I9*/[>+G&S_/"5JF]DK0GO[R;N^)`I!+9S*HQ M*1+`P5ZXF.\SR#-94#34A4=G'B5J:^6TJI'/%J>1*[M)2;'`E<2J/APKM*P$ MUA'GZ&Z`SZN>#Q:K?X#58C!=XBY3PW=FM;!,46_K6(A2<^;T8;_W25W,\;.C M?D>^\-J9&+O.,ZC%\#!'..?83DPX*1IECMV(TQ5F88)E)OE2,C0>OF'.#+V M`HT3+TB-"G/;-K_I@G$XF$_PF+!W=:4RZ5N M:3EV#'3DT^7>]_CW636Q&A_6"CAXH]D/^>'L/,WL"*-=8Q@7T#B,OCO1!L3X M>W+&:WK./?:Q\'1_VG'?*KE?T+XQCK4^L:$MQZ=H1,OMA*67,4[(`Z777W.= M1%J"QO%+'%7-)0JI>]#K*2DS2*^O-^@YRN#1,Y*I=V0NE-[QGG[5"SS1Y61- M^(RN)TLZ7GG8%67O*TSD+ZOL$"NX8DP&##X^D:B1DV!SZ&@%M.!?^7'7YB#2 M-U*[PHF`@S;&%)X,[6F\>P\W!Q_--.H6,6^>"]_@@RQYN7T[>3H3_I:(F5E` M*@?/Q>M7\,_Q"0/%K[\1B>9J7*KQAWS\:T'\6JF5.T$F9+`TY1M\&3 MQSL31$:(!>TWE=CXW3??,)5U_37*@-C06%-O<:)]-1423+K3;?C@>$S.5/,D M,F)#[G'4M<%Z*)T5CM!195,F7[0*GFFGE(KFE,O3K7N#8'/K1=!%`C[!AS6, M*FQ4C$WCG+%!?R8-.9&3Q>/=(`0&G-<6<7SAEZGL]8]ESP3 M8?9=5A);,BFY\P(X22#W=NUF5O,3D#P.X:9_\`VS`<)G1?[5*R`+)B2,M0E. M0TY\BC*WNNF.>/>+L`2-^9PX*HE],38UN/0+T%C:UQW6GL!*\K`2RFPT%Y1T MLW):*,JNZB9JZBET#&'8*?<(&4G%TYC`;0Y#(L`F0Q`A!B[A;H3SD]AD-S[S_@^.0(3=^A$ M&2A3_Y:3HGB^,PE^]0(4N((D\M8' M>M;G$D:/GEMY:XDVF1W$@#,"/*P%SN8?Q*4O;UU>),]R"..6U8HHBXFMUZ2W0\,G]Q[1(]"/6*3Q'4VRIENYO4E8B"7> M29NB%;AGK2#S_EF/4<9!J927X*'B>,5=U))=A](&+.BD=5+ZVFJT2!_R)!BE MCQCI0;[BI-=24DQN-.*B$]EGE`G`"7@F`CLB_=Z:?492..=.1`>Z\AVT/,>S M9Z=1FW?:"`_LT3LEW]NUT:C9/1OW&7%$]+O->1Q&7^'Z%L;>+LCF`H-@LX![ MQXMXL_>6\LQO@6Y$++$A&B\[(&&`2CM.]$G).A5H3?CIAKYJ/S&NT']'Z#<4 M?9Q''U&!=:F`N(F!<2LUJC;DRU3Z/OC0WE!P4K.Q3F!2E"0^B"E+$)9')X4 MQ*:7%)<4.&.+)*JRY&DB'"F`_^+BD)H@I#@"]5_E/29VG*7ZJU1-FY72Z]1M>#0G@7X1<1'&)VJ5N"3F9R=^X\TC'0#*3,4J`HL- M^4[+=UHUZZI`:$N&(^218A.L"GY+LAJBH8*DIDZ.^9RF%F&+SA+;,QIAK&T2 MFGZF6PH::92E,Q:F,7S_E&F?Z2^)H9>"D-\6[YWG/@ M1`G;XZ[UWK"V%LQ<("8MJ-=:0*/;R;$;KP%(.5=I_F_8FSH"*\S[8WEO,CS1 M[_+BMO3%>2FSA1-\?FR0XB4N1@'>(2&_H+_1_]9.#-$7_P902P,$%`````@` MR7W30@HKD\=_#P``_OD``!@`'`!H;'1H861V+3(P,3,P-#,P7W!R92YX;6Q5 M5`D``XH*PE&*"L)1=7@+``$$)0X```0Y`0``[5U?<]LV$G^_F?L.'O?9D17W M3YQIVG$L.^-I8FELI[U[TD`4).%*`3J`=.Q^^@(D95,2`0(DR)5X]Y1$`9;[ MVUT`B]WE\N=?GY;AT2/F@C#ZX;C_YO3X"-.`30F=?SC^^G!]\N[XZ-=?_OF/ MGT-"_YP@@8_D!"H^'"^B:/6^U_OV[=N;IPD/WS`^[[T]/3WKK0<>IR/?/PFR M,?K;V7ILO_>O+Y_O@P5>HA-"181H\#I+D2F:US\_/^\E_RN'"O)>)/,_LP!% M"812OHZT(]2_3M;#3M1/)_VW)V?]-T]B>JQDP%F([_#L*'G\^^AYA3\<"[)< MA8KMY+<%QS/)0Q@MT/11DNB?G7Y_=JH(?#=@0;S$-+J@TRL:D>CYALX87R9L M'Q\ITE_O;C;X7V"4$E*">1.P94^-ZAD)]6KS>1^A""OZP]DUH?+1!(4C)H@B M?QDB()7NC5QG2WP1 M1IA3J;Q'7%6FNX2\\GF)Q.(Z9-_$#9T2CH.H*I^[A.KS>8NBF./A;+C"/%D! M0BZ+(9\C2OYR7UKEU'S8J"!B.!MQ+*14W'DLFE^?JT],[OB73#Z)N[&S,;$^ M'WGZ02T^@(-&#$T]:(A[61;R2`Y4]HW!MSU4W\C):];F]1"LB MB=]'+/C3B;6-B;Y6*:LL@K;9;0:M]$J3%N2]&NQ M51@MFN_&58%W&'*>4J=XKG2G?,-SY1OV?TR8SG[^C"98XVGD'+`F*?^ZH\'-@$0VHK="7-(["18D?%'^C+-E-2%F[+!R-(Q/ M,?]P+.?$0O+)5HJ4NDRWH8=+"86C4-X5\=-O^-FHB*VQX[>'K8D".)DJ^FWK MXD+BF"HLUR&::W2P,69\=JBRWX&1R?QMVS*_C+E">DU$@,)_8\2ERS60AYA& M_+KAX^\/51,F1)E2SMI6RAK-@R2K441^R/B'0Q7^-HI,X-]#"?SEUF%8`H5C MQS\>N@IVX&2Z^`%*%Z\K\EK^(DJTL35Z_-.AZZ,`4*:1'V$UDAJ*O4YRX\?O MNJ&5+4B97GZ"\5VO28CYI5RT<\;-GNO&R/'YH>I"`R;3PCN@&P1;+AE-0H'W M"RD`,8PCE656R6WS=<(P<=P_/6PEE8++E':N45IO.T:Q+0MO<0O+M'$E2YHA M,4DT$(N3.4*KU)QP&(GU+]MVE?T\-G%E"'6X3*\>ZJ@.ZT(('`D+`)L#H8(> MKN+<7`UZ+-J0A\0WP_):D@:_#?PGS#]B/F$OH4H876:W*&N5;HV'"J+H=6/2 M80'SG5"E2K89-*?^&RKB4JJ`8GVM6>Z$>D8:MMC+I!36SU1+K'9MG(^$S0AH3S=L:K,2IS8 M!0LE+G'UWU@ZMQ:'G2T)J/"1'\_&!64WUFT.L;WGHY\$%:VJHL!2$RC`UHGC M]R((6$PC,4+/:!)B*2CY"X\E[SO831NZ/16H:)F=3C4G@!N\3AC&(,8/+%=I M9V4'^DE0@;DZ:C>CZ=R>;[?)@T7O&MG6\^&Z@W;K=N5P0X,P5B')$>.)BJ*( MDTD9/&,<1\X M/->:,9@$`.YNF(I7X#1_`:UW$9^&[L^0/\B$.V4D&7 M^PC-\942S(H3@0=X1@(2R8M3O(P3EWH0.,=.#NZX#Q[(;,EJ--CU!8R'9LCH;T?@PPU%\I=_COBW`BY"C)@QATO-P[:@7'6W@[WW?!2/G$F MQ(BS&3$MO=PH:&_$67%;O/MR.B#C-UF/*CK/JF9M7K30SH%V-IP5:D32H'/1 M:B$XFV$A$LZOL;$<97LH="6Q43O%"BV"T(F3\1.F4ABAJI&;+@E-^J$H!S$3 MC6G#-<^$KB:NH&0+1-TX48=!$*_D9>'9[,WFAT%7!U=0YS;[X'=YBCA4 M`*7Y?4$4S9.C1K.S6LR"+MQU4)@EFFZMH\-+@,7)DZM&=Q!9R=B$=6\[:` MG:UJ^K+QP[KS=M%_8A&IA2#4.[H!HP$)\0;6!^9OHVCB<=!919]&UI1\NA$> M3U[TD8Z!]'Q4A9#T=/Y`7!4?"WD#OL?\D018#/EEB,C2M$BFLIQ%>SSE48YBS:8`TN9*!SJ^U:AZMDP/-\OBHF.4;J_;_TSYSP\F__ M6!52.A""SO.V?`PYRZ8;2F?Y60A-@2A4]O-V8TM>G`OI^6`GY=`'W@2W7/LQP5V%^J$-9!OZ",6=`K?JZF4`>W&I:GTJFBN4C?/!4_Y5U1M ML9W8P84.NWFWBOS'R`=X8FY=KY\&GMMOS!8*D?ZO'2A>#A+P[E5>;<01=Q=\ M4X57WM;4'ZJMSB,*55@J_>[:]C7/8#$N9/:@=U45I\,98F.]B5HVCQ*U@[>: MJJ[.?`NIVH7=J\02)#,\VF=E`8C MJL79D,\1)7\E_VZ[$B__;/6*$@O)-#4-.AWE))#K1/*B2:O7GGW0AZCMJ\7X M@(@@9$*J^D%:RL?0?#GS_2CHND!O.B_>$YH05W-7P3;["0HBAK.\"!QV$U,5 M0`%EP]*WF`6QH#-VLH2%N3G4SEBH)64IR^*%4HBB"Y;^B4DPE[;E7H;'M:]E4J%># MZ^C49/E``54[6@^RV4WCHP M;AL`?`(`Z%K7L3S`?;#`TSC$ZOL0Q=Q]?-[X'\U'@6O1@[Z_5<\-5(;KR2,/ M8?9D.[`73\14,6U/!+J/4V4MNR64BH%WQU(&;(D(M;2(=#!T8"]/D MT^$H''ZC6*]=>"!"/TG'SJA/$[^8>*$D0+ MS(?RF?*V/%4?]C/V#K.G`M6>IX+>BA7OB'6OE5]/Z18"`.JIXT_9=AC!-W,O M!_P@QJKEV8O("!;IIS9,L2;])+#..+6U;XFMP43'WE1@`@4_]Z\0TWB;-]!S`F=IS;].PIC+)%+DQ,)[J^4%+K0E>A`5Y34-9#* MH+M14**!G6;3/1B-AA!T^4G#5F-`#=XIV:DB[0X'F#RJCD973\$"T3E>?R?- MI2!-3P6Z%,77\>((V5==2IL5J=>,_X$G`RS(G*Y/S@LZO5/=G[GY:\P5Z$&% M8!LW#%OPX%\)M321$>+)&>G#/.QH0<=J&S`->^"^OC[:M%EXLPD;N0#'MDO#1?9:H3`(\&M.*'%L'U]E[3B==?];%'OE<6A:D5C$="P M)0'6]KR=HT0#.-/]>22W0&(V@)G>NK:@3W* M0TGNM!JB!4[GU-6^)43PI,U!QV.!\SK^G<1"B+XR.`<>>@7.V7@\#HK!=3HU MTW24%3@QXSV@L)=)&-_M:=92RZY-0D)-,%_'JMW+^F.*!B-QI@6>OZED*-5@ M@F=MW`^.4L6[3`=/O7@\,0J0>4NOV+ZVTU/\3I#`\A]_`U!+`P04````"`#) M?=-"TEWMNWX'``"F/0``%``<`&AL=&AA9'8M,C`Q,S`T,S`N>'-D550)``.* M"L)1B@K"475X"P`!!"4.```$.0$``.5;W5/;.!!_9X;_P9.GWD,P@;97&*#3 M0KEACC8,T+N^=11[DV@J2SY)YN/^^EO)=F([LF,3.A>:%\:Q]K!SP0(>63X][7V_/^NY[W_F1[ZT@%4XB(IXF<@/Y" M(E`Q">"X-]4Z/O3]^_O[G2D0IJ[F!_]_6^4198`MSO[P@Y0:G=@?_M\^6- M];SGS80/&>4_2HB'D60Y9M\WPR.BH`@Q$J&>@8J`-WXZ6!)G#?J_7:*!JG+: M`*!<:1-\V4(UB"SLP<'!@6]'Y_0<@M!N6CM4`.:&!8D8XT4(^GN/O$DF"\R1R M*PJU](WW/@KU40HD#4K8Y<`"R)0VPKG01&,%/#DB<4SY6)C;YA$Z-.[>(L@S M%U^O+Y94)AO=F0@24^P^\/`3UU0_7J!&&5D+/8\B08T2,]LAC"FGUB\L95[? MRV'%2\)#+]7A%90<^54-N=)$03CD)_8:,Z90AT68FI2A,A$78JZPG7Q`6)"P M>@-^B>256+_!..P:,QR?4XYCE+`KH:RSIXPHE2TUAO^6LNY,["'],P5X_9$P MXXEW,P70:@.9SPBP\5\12;B>@J;H0$IV_;";W_U&?KU7J`-F.G[;0+X+L_<" M]VH1?&`:)%92>@<+\WM1PLWZZPKKLVOEB;$WC$':V)0M.*3["]&)A.%X/A=Q M^1S*">'TW\+:NES,S?Q;LZI2%3"A$(\_4D6.V5]4MH%Y^$@453V#X$OWJ<"[\F,U-(=-YOOJFQ:C)>!-I#%:V#F100W M"OKQ%C<<"E\OS-.;,EH[ZF;WH,INAO>L`J^H80.IODGB./VT0UB^QBV\[BP3 M95HW\96GKF:7TK),R)V-_?;U?:-3L*2( MES+14M:=D-?=Z_Y&)Z98[TM9<`VX*7_3N![\,NR:/Z:Q MHA%.L%YV;RIAC+RG5/?S7M-WC&KG(6*YE%'>T+*QF:D2D=G.561?PYN;.*A$ MX**@*:AY8\I_GI"0]JXAE3.U;@$Q,NH:$$*`K6,L.,>[QE)Y+)XW(C]OC>#5 MO&&"`QB,D-KCSIYP72,S;2=?BL"J:8"87_TW^H.]_OY@YT&%J6,=[,\B MZF@_QW6S[VX2M[2<`XS)-RV,-?9E:VQ:>TZ@#TRK_$Y_KJIMU`VMT"9?'+#L M>@4?7-WF-DX4;8H1D[*$,A7IP!3!P=M5 M/&A9"@O6]:J6FX\?M/6FJ.737$DWYQK/IK29%3G&7'1[&I<YNEKIM7ES$EV"L[ZTGP*Y,-(:4GR1F*V.?S>#I%N,NVA MLD.\1_GD0D-DWH1Z'LFDCGM:)F8+:J5PQT=%>&MQ82*S3[><,MP=FQUC*JL2 M!%.=F-$_I$CBW`A%]3W//_$60CP5422X?8N\4"HQVLH1.06*`>`HOGS*1U<( M8\*4,X9TOZCSH5%Z@N"X%T@(J7ZFR+A*F$9R,1F?L09,T@..`*H:88/@RI'. MLU4)-831,T5ZP?^D/,0P<"J-+'`XO@%Y1X-JJ,V2+R'6*RD"@%"=2Q'9^8CZ MA^/")#T7TAU[-^1+X,+1SG57I4;!-2I&Q5:J.Q*WQ)J&<`L/^B.;M7U<,11$ MTB#2@Y6'.K__Q#GW#)$L/:9A?$\(J.WJ-DE@H"C=3@D^-J1<0?@1C"OK&(:7)''[)]5KM/-]E!/ M00[O0$Z!X/Y&Z>KBWP7X$M;^[@S\*I$O:5TVSOFNV#6<^NTW^^T0+R'E"XO- M-01`[R"\X)\>@BGA$\!@[="25:H)F%5T+.=Q=F]]UN5T+X$/[]\P.@-%)SS/ M(#[)UQ`3*A?>:I^D8L65^F=MPW"5^HNP!)[(0%OX>DZ!52+O$/;/J`'/^CW' ME<[YQQMW$6R/6J?<%\Z%-*YGC8)KM'BYLW">F'?$_%M,F[Q5$2OF;,48_?0+ M],GVUG]02P$"'@,4````"`#)?=-"A["(OF(9``#(S```%``8```````!```` MI($`````:&QT:&%D=BTR,#$S,#0S,"YX;6Q55`4``XH*PE%U>`L``00E#@`` M!#D!``!02P$"'@,4````"`#)?=-"1BI:AL,%``#Z1@``&``8```````!```` MI(&P&0``:&QT:&%D=BTR,#$S,#0S,%]C86PN>&UL550%``.*"L)1=7@+``$$ M)0X```0Y`0``4$L!`AX#%`````@`R7W30F/J!,!M`P``C1@``!@`&``````` M`0```*2!Q1\``&AL=&AA9'8M,C`Q,S`T,S!?9&5F+GAM;%54!0`#B@K"475X M"P`!!"4.```$.0$``%!+`0(>`Q0````(`,E]TT(0F?1DE1L``%B``0`8`!@` M``````$```"D@80C``!H;'1H861V+3(P,3,P-#,P7VQA8BYX;6Q55`4``XH* MPE%U>`L``00E#@``!#D!``!02P$"'@,4````"`#)?=-""BN3QW\/``#^^0`` M&``8```````!````I(%K/P``:&QT:&%D=BTR,#$S,#0S,%]P&UL550% M``.*"L)1=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`R7W30M)=[;M^!P`` MICT``!0`&````````0```*2!/$\``&AL=&AA9'8M,C`Q,S`T,S`N>'-D550% K``.*"L)1=7@+``$$)0X```0Y`0``4$L%!@`````&``8`+`(```A7```````` ` end XML 11 R4.htm IDEA: XBRL DOCUMENT

Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended		37 Months Ended
Statements of Operations and Comprehensive Loss (USD $)	Apr. 30, 2013	Apr. 30, 2012	Apr. 30, 2013	Apr. 30, 2012	Apr. 30, 2013
Statements Of Operations and Comprehensive Loss [Abstract]
SALES				$ 100	$ 100
COST OF GOODS SOLD				69	69
GROSS PROFIT				31	31
EXPENSES
Professional fees	5,000	2,200	6,599	25,275	55,461
Office and general	5,873	2,998	11,814	6,442	19,298
Rent and occupancy costs	3,600	3,600	10,800	10,800	33,600
Consulting and management fees	21,000	11,000	33,000	38,000	131,000
TOTAL OPERATING EXPENSES	35,473	19,798	62,213	80,517	239,359
LOSS FROM OPERATIONS	(35,473)	(19,798)	(62,213)	(80,486)	(239,328)
Foreign exchange gain (loss)	(129)	(116)	(129)	55	(347)
NET LOSS AND COMPREHENSIVE LOSS	$ (35,602)	$ (19,914)	$ (62,342)	$ (80,431)	$ (239,675)
LOSS PER WEIGHTED NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED	$ 0.00	$ 0.00	$ 0.00	$ 0.00
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED	24,520,000	22,920,000	24,520,000	22,920,000

XML 12 R10.htm IDEA: XBRL DOCUMENT

Supplemental Cash Flow Information

9 Months Ended

Apr. 30, 2013

Supplemental Cash Flow Information [Abstract]

SUPPLEMENTAL CASH FLOW INFORMATION

5.	SUPPLEMENTAL CASH FLOW INFORMATION

During the periods ended April 30, 2013, and 2012, and for the period from inception to April 30, 2013, there were no interest or taxes paid by the Company.

The significant non cash transactions for the nine months ended April 30, 2013 consisted of the following:

a) For the nine months ended April 30, 2013, the controlling shareholder contributed management services of $2,000 per month totaling $18,000 (nine months ended April 30, 2012 - $18,000);

b) On November 14, 2012, the Company received $10,000 in exchange for 2,000,000 shares of common stock at $0.005 per share. These shares will be issued in the next quarter;

- Definition

The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References+ Details

XML 13 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'

'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'

'+ "\n"+' '+ "\n"+'

'+ "\n"+'

'+raw+'

'+ "\n"+'

'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 14 R6.htm IDEA: XBRL DOCUMENT

Nature of Operations and Organization

9 Months Ended

Apr. 30, 2013

Nature Of Operations and Organization [Abstract]

NATURE OF OPERATIONS AND ORGANIZATION

1.	NATURE OF OPERATIONS AND ORGANIZATION

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS140-4/FIN46(R)-8

-Paragraph 8, C1, C7

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 94-6

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 46R

-Paragraph 4, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6228881-111685

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 2-6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

+ Details

XML 15 R8.htm IDEA: XBRL DOCUMENT

Going Concern

9 Months Ended

Apr. 30, 2013

Going Concern [Abstract]

GOING CONCERN

3.	GOING CONCERN

XML 16 R11.htm IDEA: XBRL DOCUMENT

Capital Stock

9 Months Ended

Apr. 30, 2013

Capital Stock [Abstract]

CAPITAL STOCK

6.	CAPITAL STOCK

On November 14, 2012, the Company received $10,000 in exchange for 2,000,000 shares of common stock at $0.005 per share. These shares will be issued in the next quarter.

In January 2013, the Company agreed to issue 500,000 shares of common stock valued at $0.01 per share for a total of $5,000 for consulting services. These shares will be issued in the next quarter.

In March 2013, the Company agreed to issue 800,000 shares at a issue price of $0.01 per share. These shares will be issued in the next quarter.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section B

-Paragraph 7, 11A

-Chapter 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 20: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 21: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 22: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 23: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

+ Details

XML 17 R9.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Apr. 30, 2013

RELATED PARTY TRANSACTIONS

4.	RELATED PARTY TRANSACTIONS

Advances from a shareholder of the Company as at April 30, 2013 were $29,848 (July 31, 2012 - $25,466). These advances are non-interest bearing, unsecured and with no specific terms of repayment.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 57

-Paragraph 1-4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Article 4

+ Details

EXCEL 18 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\V,#5D-38W8U\U.3ED7S0W.&5?.6(Y.%\Q.3DQ M839B8C$T-F4B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E)E;&%T961?4&%R='E?5')A;G-A8W1I;VYS/"]X M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/DYA='5R95]O9E]/<&5R871I;VYS7V%N M9%]/#I7;W)K#I7;W)K#I% M>&-E;%=O#I%>&-E;%=O#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H M965T/@T*("`\>#I0#I%>&-E;%=O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^9F%L'0^07!R(#,P+`T*"0DR,#$S M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^,C`Q,SQS<&%N/CPO'0^43,\2!&:6QE3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^4VUA;&QE3QS<&%N/CPO3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\V,#5D-38W8U\U.3ED7S0W.&5?.6(Y.%\Q.3DQ M839B8C$T-F4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C`U9#4V M-V-?-3DY9%\T-SAE7SEB.3A?,3DY,6$V8F(Q-#9E+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAAF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XQ,#`L,#`P+#`P,#QS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^)FYB M'0^)FYB'0^)FYB'0^)FYB7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB'0^)FYB2!O<&5R871I;F<@86-T:79I=&EE2!I;G9E'0^)FYB'0^)FYB'0^ M)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^)FYB M'0^)FYB'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$ M)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)R`@8F]R9&5R/3-$,"!C96QL6QE/3-$)V1I6QE/3-$)V1I6QE M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SY(96%L=&@@061V86YC92!);F,N("AT:&4@(D-O;7!A;GDB(&]R M(")(96%L=&@@061V86YC92(I('=A2!A;F0@:7,@86X@;VYL M:6YE(')E=&%I;&5R(&]F(&AO;64@;65D:6-A;"!P28C.#(Q-SMS(&ES M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$6QE/3-$)W=I9'1H.B`Q.'!T.R<^#0H\9&EV('-T>6QE/3-$)W1E>'0M M:6YD96YT.B`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`P<'0[)SXF(S$V,#L\+V1I=CX-"CQD:78@3L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES M<&QA>3H@8FQO8VL[(&UA6QE/3-$)V1I6EN9R!U;F%U9&ET960@:6YT97)I;2!F:6YA;F-I86P@2P@=&AE>2!D;R!N;W0@:6YC;'5D92!A M;&P@;V8@=&AE(&EN9F]R;6%T:6]N(&%N9"!F;V]T;F]T97,@2!F;W(@82!F86ER('!R97-E;G1A=&EO;B!H879E(&)E96X@:6YC M;'5D960N($9O2`S,2P@,C`Q,BX\ M+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'0[(&1I3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SY4:&4@0V]M<&%N>2!I2!!4T,@.3$U M(&%R92!T:&%T('1H92!#;VUP86YY)W,@9FEN86YC:6%L('-T871E;65N=',@ M8F4@:61E;G1I9FEE9"!A'1087)T7S8P-60U-C=C7S4Y.61?-#'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)R`@8F]R9&5R M/3-$,"!C96QL6QE/3-$)V1I6QE/3-$)V1I6QE/3-$ M)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SY4:&5S92!F:6YA;F-I86P@2!O9B!T M:&4@0V]M<&%N>2!T;R!C;VYT:6YU92!A2!C;VUE(&1U92!A;F0@=&\@8V]N=&EN=64@:71S(&]P97)A M=&EO;G,L('1H92!#;VUP86YY(&ES('-O;&5L>2!D97!E;F1E;G0@=7!O;B!I M=',@86)I;&ET>2!T;R!G96YE6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`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`@("`\=&%B;&4@8VQA2!46QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)R`@8F]R9&5R/3-$,"!C96QL M6QE/3-$)V1I6QE/3-$)V1I M6QE/3-$)W1E>'0M:6YD96YT.B`P M<'0[(&1I&-H86YG92!V86QU92!W:&EC:"!R97!R97-E M;G1E9"!T:&4@86UO=6YT(&]F(&-O;G-I9&5R871I;VX@97-T86)L:7-H960@ M86YD(&%G2!T:&4@<&%R=&EE2!T M6QE M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W1E>'0M:6YD96YT.B`P M<'0[(&1I6QE/3-$)V1I2!I;B!T M:&4@86UO=6YT(&]F("0Q+#0P,"!P97(@;6]N=&@L('1O=&%L:6YG("0Q,BPV M,#`@9F]R('1H92!N:6YE(&UO;G1H2!C:&%R9V4@:6YC;'5D97,@=&AE(&AE M860@;V9F:6-E(')E;G0L('!H;VYE+"!I;G1E6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[ M(&1I6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I2`S,2P@,C`Q,B8C,38P.RTF(S$V,#LD,C4L-#8V*2X@5&AE3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\V,#5D-38W8U\U.3ED7S0W.&5?.6(Y.%\Q.3DQ839B8C$T M-F4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C`U9#4V-V-?-3DY M9%\T-SAE7SEB.3A?,3DY,6$V8F(Q-#9E+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/&1I=B!A;&EG;CTS1&IU3H@8FQO8VL[(&UA6QE/3-$)W=I9'1H.B`Q.'!T.R<^#0H\9&EV('-T>6QE/3-$)W1E>'0M M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M=V5I9VAT.B!B;VQD.R<^-2X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D/@T* M/&1I=B!A;&EG;CTS1&IU3X\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T M:6UE3L@=&5X="UI;F1E M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY$ M=7)I;F<@=&AE('!E2!T:&4@0V]M<&%N>2X\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/&1I M=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@ M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#$X<'0[(&UA3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&IU'0M:6YD96YT.B`P<'0[(&1I6QE M/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(&IU M'0M:6YD96YT.B`P<'0[(&1I3L@=&5X="UI M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA6QE/3-$)V1I3H@8FQO M8VL[(&UA2!S='EL93TS1"=T97AT M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#$X M<'0[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SYB*28C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.T]N($YO=F5M8F5R(#$T+"`R,#$R+"!T:&4@0V]M<&%N>2!R96-E M:79E9"`D,3`L,#`P(&EN(&5X8VAA;F=E(&9O6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&UA6QE/3-$)V1I2!A9W)E960@=&\@ M:7-S=64@,2PP,#`L,#`P('-H87)E2!S M='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I M=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT M.B`P<'0[(&1I7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA6QE/3-$ M)W=I9'1H.B`Q.'!T.R<^#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`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`L M,#`P('-H87)E3L@=&5X M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA6QE/3-$)V1I'0@<75A6QE/3-$)W1E M>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'0[(&1I3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY);B!*86YU87)Y(#(P,3,L('1H92!# M;VUP86YY(&%G3L@ M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P M<'0[(&1I'0@<75A3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V,#5D-38W8U\U.3ED M7S0W.&5?.6(Y.%\Q.3DQ839B8C$T-F4-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO-C`U9#4V-V-?-3DY9%\T-SAE7SEB.3A?,3DY,6$V8F(Q-#9E M+U=O'0O M:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UE;G0@9F]R M(')E;G0@86YD(&]T:&5R(&]V97)H96%D(&-O'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'1U86PI/"]S=')O;F<^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$&-H86YG93PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&-H86YG93PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC M&UL M/@T*+2TM+2TM/5].97AT4&%R=%\V,#5D-38W8U\U.3ED7S0W.&5?.6(Y.%\Q /.3DQ839B8C$T-F4M+0T* ` end XML 19 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 24 73 1 false 2 0 false 3 false false R1.htm 001 - Document - Document and Entity Information Sheet http://www.healthadvance.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 002 - Statement - Balance Sheets Sheet http://www.healthadvance.com/role/StatementOfFinancialPositionClassified Balance Sheets false false R3.htm 003 - Statement - Balance Sheets (Parenthetical) Sheet http://www.healthadvance.com/role/BalanceSheetParanthetical Balance Sheets (Parenthetical) false false R4.htm 004 - Statement - Statements of Operations and Comprehensive Loss Sheet http://www.healthadvance.com/role/StatementOfIncomeAlternative Statements of Operations and Comprehensive Loss false false R5.htm 005 - Statement - Statements of Cash Flows Sheet http://www.healthadvance.com/role/StatementOfCashFlowsIndirect Statements of Cash Flows false false R6.htm 006 - Disclosure - Nature of Operations and Organization Sheet http://www.healthadvance.com/role/NatureOfOperationsAndOrganization Nature of Operations and Organization false false R7.htm 007 - Disclosure - Basis of Presentation Sheet http://www.healthadvance.com/role/BasisOfPresentation Basis of Presentation false false R8.htm 008 - Disclosure - Going Concern Sheet http://www.healthadvance.com/role/GoingConcern Going Concern false false R9.htm 009 - Disclosure - Related Party Transactions Sheet http://www.healthadvance.com/role/RelatedPartyTransactions Related Party Transactions false false R10.htm 010 - Disclosure - Supplemental Cash Flow Information Sheet http://www.healthadvance.com/role/SupplementalCashFlowInformation Supplemental Cash Flow Information false false R11.htm 011 - Disclosure - Capital Stock Sheet http://www.healthadvance.com/role/CapitalStock Capital Stock false false R12.htm 012 - Disclosure - Nature of Operations and Organization (Details) Sheet http://www.healthadvance.com/role/NatureofOperationsandOrganizationDetails Nature of Operations and Organization (Details) false false R13.htm 013 - Disclosure - Related Party Transactions (Details) Sheet http://www.healthadvance.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) false false R14.htm 014 - Disclosure - Supplemental Cash Flow Information (Details) Sheet http://www.healthadvance.com/role/SupplementalCashFlowInformationDetails Supplemental Cash Flow Information (Details) false false R15.htm 015 - Disclosure - Capital Stock (Details) Sheet http://www.healthadvance.com/role/CapitalStockDetails Capital Stock (Details) false false All Reports Book All Reports Process Flow-Through: 002 - Statement - Balance Sheets Process Flow-Through: Removing column 'Apr. 30, 2012' Process Flow-Through: Removing column 'Jul. 31, 2011' Process Flow-Through: Removing column 'Apr. 13, 2010' Process Flow-Through: 003 - Statement - Balance Sheets (Parenthetical) Process Flow-Through: 004 - Statement - Statements of Operations and Comprehensive Loss Process Flow-Through: 005 - Statement - Statements of Cash Flows hlthadv-20130430.xml hlthadv-20130430.xsd hlthadv-20130430_cal.xml hlthadv-20130430_def.xml hlthadv-20130430_lab.xml hlthadv-20130430_pre.xml true true XML 20 R3.htm IDEA: XBRL DOCUMENT

Balance Sheets (Parenthetical) (USD $)	Apr. 30, 2013	Jul. 31, 2012
Balance Sheets [Abstract]
Capital stock, par value	$ 0.001	$ 0.001
Capital stock, shares Authorized	100,000,000	100,000,000
Capital stock, shares Issued	24,520,000	24,520,000
Capital stock, shares outstanding	24,520,000	24,520,000

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References+ Details

XML 21 R14.htm IDEA: XBRL DOCUMENT

Supplemental Cash Flow Information (Details) (USD $)	0 Months Ended	1 Months Ended		9 Months Ended		37 Months Ended
Supplemental Cash Flow Information (Details) (USD $)	Nov. 14, 2012	Jan. 31, 2013	Dec. 31, 2012	Apr. 30, 2013	Apr. 30, 2012	Apr. 30, 2013
Supplemental Cash Flow Information (Textual)
Monthly in-kind contribution by controlling shareholder				$ 2,000
In-kind contribution of services by controlling shareholder				18,000	18,000	56,000
Common stock shares received in exchange, value	10,000
Common stock shares received in exchange, shares	2,000,000
Par value of common stock shares received in exchange	$ 0.005
Common stock shares issued for web design services and repairs, shares			1,000,000
Par value of common stock shares issued for web design services and repairs			$ 0.01
Common stock shares issued for web design services and repairs, value			10,000
Common stock shares issued for consulting services, shares		500,000
Par value of common stock shares issued for consulting services		$ 0.01
Common stock shares issued for consulting services, value		$ 5,000

XML 22 R5.htm IDEA: XBRL DOCUMENT

Statements of Cash Flows (USD $)	9 Months Ended		37 Months Ended
Statements of Cash Flows (USD $)	Apr. 30, 2013	Apr. 30, 2012	Apr. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (62,342)	$ (80,431)	$ (239,675)
Adjustments to reconcile net loss to net cash used in operating activities:
Common stock issued for services		15,000	80,000
In-kind contribution of services	18,000	18,000	56,000
Issuance of common stock for services	15,000		15,000
Changes in operating assets and liabilities:
Prepaid expenses	1,164	25,000
Accounts payable and accrued liabilities	4,820	1,041	14,453
Net cash used in by operating activities	(23,358)	(21,390)	(74,222)
Net cash provided by investing activities
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock	18,000		44,600
Advances from stockholder	4,382	12,846	29,848
Net cash provided by financing activities	22,382	12,846	74,448
NET INCREASE (DECREASE) IN CASH	(976)	(8,544)	226
CASH, BEGINNING OF PERIOD	1,202	8,843
CASH, END OF PERIOD	$ 226	$ 299	$ 226

XML 23 R2.htm IDEA: XBRL DOCUMENT

Balance Sheets (USD $)	Apr. 30, 2013	Jul. 31, 2012
Current Assets
Cash	$ 226	$ 1,202
Prepaid expenses		1,164
Total Assets	226	2,366
Current Liabilities
Accounts payable and accrued liabilities	14,453	9,633
Advances from shareholder	29,848	25,466
Total Liabilities	44,301	35,099
Stockholders' Deficit
Capital stock, $0.001 par value; Authorized 100,000,000; Issued and outstanding 24,520,000 (July 31, 2012 - 24,520,000)	24,520	24,520
Additional paid in capital	138,080	120,080
Common stock issuable	33,000
Deficit accumulated during the development stage	(239,675)	(177,333)
Total Stockholders' Deficit	(44,075)	(32,733)
Total Liabilities and Stockholders' Deficit	$ 226	$ 2,366

XML 24 R13.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details) (USD $)			9 Months Ended
Related Party Transactions (Details) (USD $)	Apr. 30, 2013	Jul. 31, 2012	Apr. 30, 2013 Shareholder and Director [Member]	Apr. 30, 2012 Shareholder and Director [Member]	Apr. 30, 2013 Shareholder [Member]	Jul. 31, 2012 Shareholder [Member]
Related Party Transactions (Textual)
Monthly payment for rent and other overhead costs to a shareholder and director			$ 1,400
Total payment for rent and other overhead costs to a shareholder and director			12,600	12,600
Advances from shareholder	$ 29,848	$ 25,466			$ 29,848	$ 25,466

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).

+ References+ Details

XML 25 R12.htm IDEA: XBRL DOCUMENT

Nature of Operations and Organization (Details)	9 Months Ended
Nature of Operations and Organization (Details)	Apr. 30, 2013	Feb. 14, 2013	Jul. 31, 2012
Nature of Operations and Organization (Textual)
Forward split for issued and outstanding common shares	10-for-1
Common stock shares issued before stock split		2,452,000
Common stock shares outstanding before stock split		2,452,000
Common stock shares issued after stock split	24,520,000		24,520,000
Common stock shares outstanding after stock split	24,520,000		24,520,000

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References+ Details

- Definition

Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.

+ References+ Details

XML 26 R7.htm IDEA: XBRL DOCUMENT

Basis of Presentation

9 Months Ended

Apr. 30, 2013

Basis Of Presentation [Abstract]

BASIS OF PRESENTATION

2.	BASIS OF PRESENTATION

XML 27 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 28 R15.htm IDEA: XBRL DOCUMENT

Capital Stock (Details) (USD $)	0 Months Ended	1 Months Ended
Capital Stock (Details) (USD $)	Nov. 14, 2012	Mar. 31, 2013	Jan. 31, 2013	Dec. 31, 2012
Capital Stock (Textual)
Common stock shares received in exchange, value	$ 10,000
Common stock shares received in exchange, shares	2,000,000
Par value of common stock shares received in exchange	$ 0.005
Common stock shares issued for web design services and repairs, shares				1,000,000
Par value of common stock shares issued for web design services and repairs				$ 0.01
Common stock shares issued for web design services and repairs, value				10,000
Common stock shares issued for consulting services, shares			500,000
Par value of common stock shares issued for consulting services			$ 0.01
Common stock shares issued for consulting services, value			$ 5,000
Shares to be issued in next quarter		800,000
Par value of shares to be issued in next quarter		$ 0.01

XML 29 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	9 Months Ended
Document and Entity Information	Apr. 30, 2013	Jun. 18, 2013
Document and Entity Information [Abstract]
Entity Registrant Name	Health Advance, Inc.
Entity Central Index Key	0001531477
Amendment Flag	false
Current Fiscal Year End Date	--07-31
Document Type	10-Q
Document Period End Date	Apr. 30, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		24,520,000